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Zusammenfassung 
Murine double minute (MDM)-2 fördert als E3 Ubiquitin Ligase das Überleben von 
Tumorzellen, indem es den Zellzyklus-Regulator p53 degradiert. Die Hemmung von MDM2 
durch sogenannte cis-imidazol-Nutline wird zurzeit in klinischen Studien zur Tumortherapie 
untersucht. Wir konnten beobachten, dass MDM2 auch in renalen Epithelzellen stark 
exprimiert wird, beispielsweise in den Tubuluszellen sowie den Podozyten. Um 
herauszufinden, ob MDM2 regeneratives Zellwachstum fördert, untersuchten wir die Wirkung 
eines MDM2-Inhibitors, Nutlin-3a, während der tubulären Heilung nach postischämischen 
akuten Nierenversagen, sowie in den Podozyten nach Adriamycin-induziertem chronischen 
Nierenversagen. 
In Übereinstimmung mit unserer Hypothese konnten wir beobachten, dass der Einsatz von 
Nutlin-3a nach postischämischen akuten Nierenversagen in C57BL6 Wildtyp-Mäusen die 
tubuläre epitheliale Heilung verschlechtert. Dieser Effekt war p53-abhängig. Allerdings 
konnten wir einen zweiten Effekt beobachten, nämlich dass die MDM2-Blockade ebenfalls 
eine Verringerung der Tubulusnekrose unmittelbar nach Schädigung bewirkte, indem die 
sterile inflammatorische Reaktion gehemmt wurde. Diesen zweiten Effekt konnten wir 
ebenfalls in p53-defizienten Mäusen beobachten, was uns schließen lässt, dass es einen 
zweiten, p53-unabhängigen proinflammatorischen Signalweg von MDM2 gibt. In vitro-
Experimente bestätigten, dass MDM2 zur mRNA-Expression und Sekretion NF-κB-
abhängiger Zytokine nach Toll-like-Rezeptor-Stimulation benötigt wird, indem die Bindung 
von NF-κB an Promoter-Bindestellen verstärkt wird. Folglich verknüpft MDM2 sowohl die 
Entzündungsreaktion als auch die epitheliale Heilung nach akutem Nierenversagen. Es 
verstärkt die Entzündungsreaktion unmittelbar nach der Schädigung, fördert dann aber in 
einer zweiten Phase die Regeneration beschädigter Tubuli. Diesen zusätzlichen biologischen 
Funktionen muss Beachtung geschenkt werden, wenn eine MDM2-Inhibitionstherapie für die 
Behandlung des akuten Nierenversagens in Betracht gezogen wird.  
Da MDM2 auch in Podozyten stark exprimiert wird vermuteten wir, dass eine MDM2-
Blockade während der glomerulären Schädigung die Zahl apoptotischer Podozyten verstärken 
würde und sich Proteinurie und Glomerulosklerose manifestieren. Die MDM2-Blockade in 
der frühen Phase der Adriamycin-induzierten Nephropathie in Balb/c-Mäusen hatte jedoch in 
unerwarteter Weise einen gegenteiligen Effekt und führte zu einer Verringerung der 
intrarenalen Zytokin- und Chemokinexpression, der Anzahl glomerulären Makrophagen und 
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T-Zellen, sowie der Kreatinin- und Harnstoff-Plasmaspiegel. Auch in Zellkultur kultivierte 
Podozyten reagierten nicht mit verstärkter Apoptose, nachdem sie Adriamycin ausgesetzt 
waren. Vielmehr bewirkte Adriamycin eine Verringerung sowohl abberante Zellkernteilungen 
als auch des Zelltods aneuploider Podozyten, hier bezeichnet als mitotische Katastrophe 
(mitotic catastrophe). In Übereinstimmung hierzu bewirkte die MDM2-Blockade einen 
Anstieg von p21 und verhinderte die Ausbildung von Mitosen in vivo, wohingegen TUNEL+ 
apoptotische Podozyten nicht erkennbar waren. Folglich stellt die mitotische Katastrophe 
einen bislang unbeachteten Mechanismus für den Verlust von Podozyten dar, in welchem 
MDM2 die Podozyten zur vollständigen Mitose bewegt. In Abwesenheit der Zytokinese führt 
dies jedoch zu Aneuploidie und zum Zelltod. Überdies bewirkte die verspätete MDM2-
Blockade ebenfalls eine Verringerung der Kreatinin- und Harnstoff-Plasmaspiegel, der 
Tubulusatrophie, der Leukozyten-Anzahl im Interstitium, der Zytokin-Expression sowie der 
interstitiellen Fibrose. In Zusammenschau der Erkenntnisse könnte die MDM2-Blockade mit 
Nutlin-3a einen neuen Therapie-Ansatz für die Prävention von renaler Entzündung, 
Podozytenverlust, Glomerulosklerose, Proteinurie und fortschreitender Nierenerkrankung 
darstellen. 
 
Trotz alledem beinhaltet die therapeutische MDM2-Blockade das Risiko einer 
unvollständigen tubulären Heilung nach akutem Nierenversagen. Auf der anderen Seite 
könnte es die progressive Zerstörung der Glomeruli stark verlangsamen oder sogar aufhalten 
und so das chronische Nierenversagen verhindern, indem es die Podozyten direkt vor einem 
Zelltod durch mitotischen Katastrophe schützt.  
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Summary 
Murine double minute (MDM)-2, an E3 ubiquitin ligase, promotes cancer cell survival and 
growth, by degrading the cell cycle regulator p53. Antagonism of MDM2 by the small-
molecule cis-imidazoline nutlin analogs is currently under study for cancer therapy. We 
observed that MDM2 is strongly expressed by the epithelial cells in the kidney for example, 
tubular epithelial cells and podocytes. To test whether MDM2 promotes regenerative cell 
growth, we studied the effects of MDM2 antagonist, nutlin-3a on tubule cell healing during 
postischemic acute kidney injury and on podocytes during adriamycin induced chronic renal 
failure. 
Consistent with the hypothesis, we observed that treatment with nutlin-3a impaired tubular 
cell regeneration during postischemic AKI in C57Bl6 wild-type mice in a p53-dependent 
manner. However, MDM2 blockade also prevented tubular necrosis by suppressing sterile 
inflammation during the early postischemic phase. This effect also occurred in p53-deficient 
mice, indicating a second, pro-inflammatory, p53-independent role for MDM2 in AKI. In-
vitro experiments confirmed that MDM2 is required to induce mRNA expression and 
secretion of NF-κB-dependent cytokines upon Toll-like receptor stimulation by enhanced 
binding of NF-κB to cytokine promoter–binding sites. Thus, MDM2 links inflammation and 
epithelial healing during AKI. It promotes the inflammatory response after the injury at the 
same time it drives the regeneration of injured tubular epithelium. Therefore, these additional 
biological functions need to be regarded when considering MDM2 inhibition therapy in 
patients with acute renal failure.  
Since, podocytes strongly express MDM2, we hypothesized that blocking MDM2 during 
glomerular injury may enhance podocyte apoptosis, proteinuria and glomerulosclerosis. 
However, unexpectedly MDM2 blockade in early adriamycin nephropathy in Balb/c mice 
had the opposite effect and reduced intrarenal cytokine and chemokine expression, 
glomerular macrophage and T cell counts, plasma creatinine and BUN levels. In cultured 
podocytes exposed to adriamycin, MDM2 blockade did not enhance podocyte apoptosis but 
rather prevented aberrant nuclear divisions and death of aneuploid podocytes, i.e. mitotic 
catastrophe. Accordingly, MDM2 blockade induced p21 and prevented podocyte mitosis in-
vivo while TUNEL+ apoptotic podocytes were not detected. Thus, mitotic catastrophe is a 
previously unrecognized variant of podocyte loss where MDM2 promotes podocytes to 
complete the cell cycle, which in the absence of cytokinesis, leads to podocyte aneuploidy 
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and death. Furthermore, delayed MDM2 blockade also reduced plasma creatinine levels, 
BUN, tubular atrophy, interstitial leukocyte numbers and cytokine expression as well as 
interstitial fibrosis. Together, MDM2 blockade with nutlin-3a could be a novel therapeutic 
strategy to prevent renal inflammation, podocyte loss, glomerulosclerosis, proteinuria, and 
progressive kidney disease.  
 
In conclusion, therapeutic MDM2 blockade may hold the risk of impaired epithelial healing 
in AKI. On the other hand it may delay or halt the progression of glomerular disorders to 
CKD by reducing renal inflammation and by directly protecting podocytes from cell death by 
mitotic catastrophe. 
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1. Introduction 
1.1 Acute Kidney Injury 
Acute kidney injury (AKI), formerly known as `Acute renal failure´, is a common and 
harmful condition occurring with high prevalence in hospitalized patients. The causes of AKI 
can be pre-renal (hypotension or shock), renal (acute interstitial nephritis, acute glomerular or 
vasculitic renal diseases; other non-specific conditions like ischemia or toxic injury) and post-
renal (obstructive nephropathy). According to the Kidney Disease: Improving Global 
Outcomes (KDIGO), AKI is defined based on serum creatinine (Scr) and urine output as any 
of the following: 
1. Increase in Scr by ≥ 0.3mg/dl (≥ 26.5µmol/dl) within 48hrs; or 
2. Increase in Scr to ≥ 1.5 times baseline, which is known or presumed to have occurred 
within the prior 7 days; or 
3. Urine volume < 0.5 ml/kg/h for 6 hours. 
 
The incidence of AKI in hospitalized patients is reported to be 2-7%, with around 5-10% 
more in ICU patients
1
. Even though there are many advances in the knowledge and strategies 
to prevent AKI in recent years, the mortality rate remains high in patients of AKI; generally 
reported to be in the range of 30 to 70% and more than 50% in ICU patients
1
. Renal 
ischemia/reperfusion injury (IRI) often contributes to AKI
2
.  
Renal IRI is caused by the impaired oxygen and nutrient supply to the kidney resulting in 
stress on the tubular epithelial cells. If the stress is severe, then death of these cells occurs 
either by apoptosis or necrosis resulting in functional impairment of kidney
3
. The 
pathophysiology of renal IRI is described in detail below. 
 
1.1.1 Pathophysiology of renal ischemia/reperfusion injury (IRI) 
The pathogenesis of IRI is complex. In simple words, ischemia/reperfusion is a pathological 
condition characterized by an initial restriction of blood supply to kidney followed by the 
restoration of perfusion and re-oxygenation. The imbalance between demand and supply of 
nutrients and oxygen results in hypoxia, and surprisingly restoration of the blood flow and re-
oxygenation results in profound inflammatory response called reperfusion injury
4
. 
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Figure 1 Pathophysiology of IRI A. The normal tubular epithelial cells lose their brush border and polarity 
upon ischemia reperfusion injury. If the hypoxic conditions remain for a long time, the cells die either by 
apoptosis or necrosis. This is followed by profound inflammatory response, in which the circulating leukocytes 
infiltrate into the kidney. Viable epithelial cells or the progenitor or stem cells then migrate and cover the 
denuded epithelial areas of the basement membrane. These cells then undergo dedifferentiation, proliferation to 
replace the lost epithelial cells. At last they differentiate to regain the previously lost polarity of the epithelium. 
(The image is adapted from Bonventre JV et. al.
3
 with modifications) B, C, D. The photographs show various 
processes occurring in the kidney after IR injury. B. Paraffin-Acid Schiff staining shows the necrosis of tubules. 
C. TUNEL staining shows the apoptosis of tubules D. Ki67 staining shows the repair process. Ki67 positive cells 
are enormously increased after the injury.  
 
1.1.1.1 Injury 
Epithelial cells in the S3 segment of the proximal tubule are the most affected cells after 
ischemic insult in the kidney
3
. Injury to the epithelium results in rapid loss of cytoskeletal 
integrity and cell polarity
5
. There is shedding of the proximal tubule brush border
4
; loss of 
polarity along with mislocalization of adhesion molecules as well as membrane proteins such 
as Na
+
-K
+
-ATPase and β-integrins6; disruption of cell-cell interactions at adherent and tight 
junctions
2
. There are also changes in actin localization from apical to lateral cell membrane
6
. 
Cells undergo apoptotic and necrotic cell death. Some literature describe that tubular cells 
undergo autophagy to maintain homeostasis and protect themselves against ischemic injury
7
. 
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When the ability of these cells to undergo autophagy is blocked, the cells accumulate 
malformed mitochondria and undergo apoptosis. 
Injured tubular cells produce kidney injury molecule (KIM)-1 (mainly by proximal tubules) 
and neutrophils gelatinase-associated lipocalin (NGAL) (mainly by distal tubules). Presence 
of these proteins in urine has been found to be useful novel noninvasive biomarkers of AKI
3
.  
Renal vasculature also plays an important role in the pathogenesis of IRI since it brings 
nutrients and oxygen to the epithelial cells. The integrity of vasculature is governed by the 
endothelium and an injury to endothelial cells as well as subsequent distortion of the 
peritubular capillary blood flow are characteristics of IRI
5
. The outer medulla of the kidney is 
at low oxygen tension owing to the countercurrent exchange properties of the vasa recta. 
Therefore, diminished or impaired blood flow to the outer medulla, due to arteriolar 
vasoconstriction, leads to death of proximal tubular cells during ischemia
3
. 
Injured endothelial cells further contribute to pathology of ischemic AKI. There are enhanced 
interactions with the leukocytes due to increased expression of adhesion molecules like 
ICAM-1 and increased expression of counter receptors on leukocytes
8
. This leads to 
activation and transmigration of leukocytes, production of cytokines and profound 
inflammatory response which contributes to AKI
3
. 
 
Regulation of tubular cell death  
The cellular and molecular mechanisms that regulate tubular cell death and regeneration in 
AKI are not completely understood and remain under debate
9,10
. A number of intracellular 
signaling cascades are activated and upregulated during and following a cell injury from 
ischemia, trauma, toxins, or infections. Ischemic renal injury has been traditionally associated 
with tubular cell necrosis. Early attempts at preventing and treating ischemic injury were 
primarily targeted at this "necrotic" phenotype and generally met with moderate success. 
However, recently apoptosis has emerged as a significant mode of cell death during ischemic 
renal injury
11,12
.  
p53 is the master regulator of cell cycle and apoptosis
13
. Once activated by a variety of 
stimuli, like ischemia, radiation etc., it induces cell cycle arrest or apoptosis in response to 
DNA damage.  Several recent studies have shown that the expression of p53 increases in renal 
parenchymal cells during AKI and this has a detrimental impact on renal tubular 
regeneration
9,14-16
. 
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Furthermore, Linkermann et.al. have provided an evidence for a programmed necrosis, termed 
as ‘necroptosis’, of tubular cells associated with renal IRI. They used necrostatin-1, a highly 
specific inhibitor of receptor-interacting protein (RIP) kinase 1 which mediates necroptosis 
and demonstrated that the kidneys treated with necroststin-1 were protected from renal IRI. 
Suggesting that necroptosis, a novel form of programmed necrosis, has a functional relevance 
in pathophysiology of renal IRI and that necrostatin-1 has a potential to prevent or treat renal 
IRI
17,18
. 
 
1.1.1.2 Inflammation 
Both the innate and adaptive immune responses contribute in the pathology of ischemic AKI. 
Innate immunity is activated in an antigen independent manner as soon as the injury happens. 
Infiltrating leukocytes viz. neutrophils, monocytes/macrophages, DCs, NK cells, and natural 
killer T (NKT) cells fabricate the innate component whereas the adaptive component is 
constructed by DC maturation and antigen presentation, T lymphocyte proliferation and 
activation, and T to B lymphocyte interactions.  
 
Innate immunity 
Innate immunity orchestrates the pro-inflammatory response during ischemic kidney injury. It 
is the immediate preprogrammed response to tissue injury which is composed of infiltrating 
cells (neutrophils) plasma proteins (complement) and physical barriers
19
. It has been found 
that Toll-Like Receptors (TLRs)
20
 and the reactive oxygen species (ROS)
21
 are the initiators 
of the innate immune response after ischemic injury. 
TLRs belong to the family of pattern recognition receptors (PPRs) which can recognize 
pathogen derived and non-pathogen derived immunostimulatory molecules
22
. The TLRs 
involved in the recognition of nucleic acids (TLR3, TLR7, TLR8 and TLR9) are localized 
within endolysosomal compartments, whereas other TLR family members (TLR1, TLR2, 
TLR4, TLR5 and TLR6) are found at the cell surface
23
. Amongst all these receptors, TLR2/4 
are known to mediate inflammatory responses in the ischemic kidney
24
.  
TLR2/TLR4 are present on both tubular epithelial cells as well as the immune cells. Their 
expression is increased in the kidney after injury suggesting their participation in the 
injury
25,26
. They recognize some of the intracellular molecules that are released during renal 
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cell death, referred as danger associated molecular patterns (DAMPs) for e.g. histones
27
, 
HMGB1
28
, biglycans
29
, hyaluronan
30
, heat shock proteins
31
 etc. and thereby activate the 
sterile inflammatory response in the injured kidney. Moreover, hypoxia generated by ischemia 
reperfusion increases TLR4 activation
32
 and mice with TLR4 deletion are protected from 
ischemic kidney injury
26
. 
Stimulation of TLR2/4 results in activation of MyD88 dependent signaling pathway. This 
subsequently activates the transcription factors such as NF-κB and AP-1 (activator protein-1) 
through the canonical IKK complex and the MAPK, ERK (extra cellular-signal-regulated 
kinase), JNK (c-jun N-terminal kinase) and p38 pathway respectively for the transcription of 
inflammatory cytokine genes
33
. In the rested state, NF-κB proteins are generally present in the 
cytoplasm in association with their inhibitory protein IκB. After activation, the IκB protein is 
phosphorylated, ubiquitylated and subsequently degraded by the proteasome, allowing NF-κB 
complexes to translocate to the nucleus and bind its cognate DNA binding sites to regulate the 
transcription of a large number of target genes, including genes coding for cytokines, 
chemokines, stress-response proteins and anti-apoptotic proteins
34
. Many preclinical studies 
have shown that inhibition of NF-κB protected the kidneys from ischemic injury suggesting 
an important role of NF-κB signaling in ischemic AKI35,36. 
 
Tubular cells 
Tubular cells are not only the victim of the injury but also an active participator in the 
inflammatory response after the injury. They express the TLRs, complement and complement 
receptors. They are known to generate several pro inflammatory molecules including 
cytokines and chemokines such as TNF-α, IL-6, MCP-1, IL-18, TGF-β and RANTES, which 
then attract the inflammatory cells in the kidney
3
.  
 
Neutrophils, Lymphocytes, and Macrophages 
Neutrophils are referred as a first line of defense, meaning that they are the first defensive cell 
type to be recruited at the site of inflammation. In accordance with this, a robust influx of 
neutrophils is also observed in the kidneys after ischemia reperfusion. Upon activation, 
neutrophils produce number of cytotoxic substances including ROS molecules, such as 
superoxide anions, hypochloride, hydrogen peroxide etc
37
. It has been noted that lowering the 
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infiltration of neutrophils in the injured kidneys, as found in Icam-1-deficient mice kidneys 
and using anti-neutrophils serum injections, protected the kidneys from ischemic renal injury
8
. 
T cells are also reported to take part in the ischemic AKI by inducing infiltration of 
neutrophils in the injured ischemic kidneys. Both the Interferon gamma producing CD4+ T 
cells
38
 and B cells are emerging as important contributors in ischemic renal injury. B cell 
deficiency also protects mice from renal ischemia reperfusion injury
39
. 
Macrophages infiltration occurs several hours after the renal injury. The role of macrophages 
in ischemic injury is very complex since macrophage activation can either be pro-
inflammatory or anti-inflammatory depending on the macrophage phenotype
40
. However, 
there are evidences suggesting little role of macrophages in tissue injury, although they may 
be involved in the repair
41
. 
 
1.1.3 Repair 
Some parts of the kidney have an extensive capacity to undergo regeneration or repair after 
injury, in contrast to other vital organs like heart or brain. Under normal circumstances the 
tubular cells divide at very slow rate but upon injury the speed of mitosis raises enormously
42
. 
Cell proliferation compensates for the loss of tubular cells by cell death. 
There is an ongoing debate about whether the cells that replenish the epithelial cell population 
after injury originate from endogenous surviving epithelial cells, bone marrow stromal cells 
(BMSCs), or intra-renal progenitor cells. Studies document that the surviving epithelial cells 
after an ischemic injury spread, dedifferentiate, and migrate to cover the exposed areas of the 
basement membrane, and then proliferate to restore cell number
43,44
. Even though some early 
studies predicted the involvement of bone marrow stromal cells in epithelial repair after 
injury
45,46
 recent literature rules out their participation in regeneration of post-ischemic 
kidneys
44,47
.  
To address the involvement of intra-renal progenitor cells in epithelial repair, genetic fate-
mapping techniques were employed in transgenic mice and results demonstrated that 
surviving tubular cells after injury, and not the progenitor cells, participate in post-ischemic 
regeneration
44
. In another study using the unbiased DNA analog-based approach, it has found 
that repair of injured proximal tubules does not involve specialized progenitors
48
. However, a 
recent study from Angelotti ML et. al., identified, with help of the sophisticated techniques 
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like Microarray and Flow Associated Cell Sorting (FACS), the new progenitor cells 
population (CD133
+
CD24
+
CD106
-
 cells), residing in proximal as well as in distal convoluted 
tubules. They have also demonstrated that these cells have the capacity to undergo 
proliferation and replace the injured tubular epithelial cells after AKI
49
. 
 
Cell cycle and repair 
The re-entry of epithelial cells into the cell cycle after an injury has been viewed as a repair 
response to the loss of adjacent cells after an initial insult, but this has become more 
complicated with the upcoming literature. It has been observed that the inhibition of epithelial 
cell cycle, using p21 adenovirus or the drugs like roscovitine and olomoucine, has completely 
protected the mouse proximal tubular cells in culture from the cisplatin induced apoptosis
50
. 
The pathophysiology of cisplatin nephrotoxicity is similar to IRI since, cisplatin also causes 
an extensive necrosis of the proximal tubular cells in the S3 segment
51
. It has also been noted 
that inhibition of cyclin dependent kinases 2/4/6 (CDK2/4/6), the key mediators of cell cycle 
checkpoint progression from G1 to S phase, using a broad spectrum of small molecule CDK 
inhibitors has protected renal epithelial cells from cisplatin induced cell death both in-vitro 
and in-vivo
52
. Moreover, mice lacking p21
CIP
 CDK inhibitor exhibited exacerbated kidney 
ischemic injury, again emphasizing that the cell cycle inhibition protects kidney again IRI
53
. 
However, it should be noted that, the cell cycle arrest of epithelial cells in G2/M phase 
induced progressive interstitial fibrosis in the kidney and also increased cell apoptosis
54
. 
Further, inhibition of CDK2 does not only induce G1 cell cycle arrest but also blocks the cells 
in G2/M or an intra-S phase of the cell cycle
55
. Therefore, even though the inhibition of CDK2 
offers early protection from AKI, long term G2/M arrest would likely be an undesirable long 
term effect. The more specific inhibitors of CDK are currently in pre-clinical studies to 
evaluate their efficacy and safety compared to the broad spectrum small molecule inhibitors 
of CDK.  
 
1.2 Chronic Kidney Disease 
Chronic Kidney Disease (CKD) is the gradual and progressive loss of kidney function leading 
to End stage renal disease (ESRD), which requires renal replacement therapy for survival. Its  
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Table 1 Severity of kidney disease (adopted and modified from Levey et. al.
56
) 
 
definition is based on the decline in glomerular filtration rate (GFR) and kidney damage with 
the increase in proteinuria (urine albumin/creatinine ratio). KDIGO defines CKD
56
 as follows: 
1. Kidney damage or GFR < 60 mL/min/1.73 m2 for 3 months or more, irrespective of 
cause; or 
2. Albumin-to-creatinine ratio > 30mg/g in two of the three spot urine specimens. 
Kidney disease severity is classified into five stages according to the level of GFR (Table 1). 
 
The CKD affects 14 to 15% of the adult US population and is projected to increase by 50% in 
the next 20 years
57
. The causes of CKD are diabetes, obesity, hypertension, medications and 
infections. Amongst different forms of CKD, progressive glomerulosclerosis accounts for the 
vast majority of cases. Focal segmental glomerulosclerosis (FSGS) is one of the most 
common forms of acquired glomerular disease leading to ESRD. It accounts for 20% cases of 
the nephrotic syndrome in children and 40% of such cases in adults
58
. 
 
Stage Description GFR 
ml/min/1.73m
2
 
Related Terms 
1 Kidney damage with normal 
or increase in GFR 
≥ 90 Albuminuria, Proteinuria, 
Hematuria 
2 Kidney damage with mild 
decrease in GFR 
60-89 Albuminuria, Proteinuria, 
Hematuria 
3 Moderate decrease in GFR 30-59 Chronic renal insufficiency, early 
renal insufficiency 
4 Severe decrease in GFR 15-29 Chronic renal insufficiency, early 
renal insufficiency, pre-ESRD 
5 Kidney failure <15 (or dialysis) Renal failure, uremia, end-stage 
renal disease 
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1.2.1 Focal Segmental Glomerulosclerosis 
Focal segmental glomerulosclerosis (FSGS) is not a single disease but is a clinicopathological 
syndrome sharing a common glomerular lesion. It is mediated by diverse insults directed to or 
inherent within the podocyte. Hence also referred as a podocyte disease or a podocytopathy
59
. 
An injury to podocytes leads to effacement of podocyte foot processes leading to proteinuria 
and glomerulosclerosis
60
. In spite of the name the lesions of FSGS are not always focal, 
segmental or sclerotic.  
 
1.2.2 Pathogenesis of FSGS 
 Loss of glomerular filtration barrier 
Glomerular filtration barrier is responsible for regulating the efficient filtration of around 180 
liters of blood every day in the kidney. Glomerular filtration barrier comprises of fenestrated 
glomerular endothelial cells (inner blood interface), glomerular basement membrane (GBM) 
(at the center), and highly differentiated and polarized epithelial cells called `podocytes´ 
(outer urinary interface)
61
 (Figure 2). 
 
Podocytes 
Podocytes are terminally differentiated glomerular visceral epithelial cells. They resemble to 
neurons in their large cell body and elongated cellular extensions, which are known as foot 
processes. These foot processes extend around the capillary loop to cover the GBM. They also 
interdigitate with neighboring podocytes by slit diaphragm
62
. A slit diaphragm is a zipper like 
structure which provides most important size-selective sieve of glomerular filtration barrier
62
. 
These terminally differentiated cells cannot undergo cell division and repair/regeneration, 
making podocyte depletion through detachment, apoptosis, or necrosis a critical mediator of 
glomerulosclerosis
63
, This means, the structural and functional alterations in the podocyte and 
its slit diaphragm are important in the pathogenesis of FSGS and other glomerular diseases. 
Several experimental models have addressed whether podocyte depletion or specific podocyte 
injury is sufficient to induce FSGS
60,64,65
. The data from these studies suggests that the degree 
of podocyte depletion positively correlates with the severity of the disease.  Loss of more than 
20% podocytes leads to overt FSGS indicating the disease threshold.  
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Figure 2 Schematic representations of glomerulus and glomerular cells The glomerular filtration barrier 
comprised of fenestrated glomerular endothelial cells, glomerular basement membrane and podocytes. The 
parietal epithelial cells are present along the bowman´s basement membrane. (The image was adapted and 
modified from Leeuwis J.W. et. al.
66
) 
 
Glomerular basement membrane (GBM) 
The basement membrane of the glomerular capillaries (GBM) is much thicker than the 
basement membrane in other vascular beds
67
. It is assembled through an interweaving of type 
IV collagen with laminins, nidogen, and sulfated proteoglycans. Mutations of the genes 
encoding these components of GBM cause glomerular disease in both humans and mice
68
. For 
e.g. mutations in collagen chains leads to alport´s syndrome, a hereditary 
glomerulonephritis
69
. Studies in laminin β2-knockout mice have revealed that proteinuria 
appeared before any structural alterations in podocytes were observed
70
, suggesting that 
alterations in GBM may leads to proteinuric nephrotic syndrome. However, the loss of normal 
GBM structure might cause alterations in the functions of podocytes and endothelial cells 
leading to proteinuria and glomerulosclerosis
71
. 
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Glomerular endothelial cells and Glomerular Mesangium 
The glomerular endothelial cells have a high density of fenestrae. The size of fenestrae is 
usually larger than the size of albumin, suggesting that the endothelial cells do not contribute 
to permselectivity of the glomerular filtration barrier. However, they do have charge-selective 
properties and the barrier probably begins at the endothelial level
67
. Glomerular mesangium is 
composed of mesengial cells and the mesangial matrix, produced by mesengial cells. Primary 
function of mesangium is to maintain structure and function of glomerular filtration barrier, 
but their overall contribution to permselectivity is very less
67
. 
 
Parietal epithelial cells 
So far the main focus of all the studies on glomerular disease was on the constituents of 
glomerular filtration barrier. However, in recent years, several studies have demonstrated that 
PECs are involved in the extracapillary proliferation, inflammation and in the development of 
FSGS
72
. Smeets et. al. have studied the development of FSGS in Thy-1.1 transgenic mice, 
which expresses the mouse Thy-1.1 antigen on podocytes. They observed that an injection of 
monoclonal antibody directed against the Thy-1.1 antigen have induced FSGS lesions with 
prominent epithelial cell hyperplasia
73
. 
 
Genetic susceptibility 
Mutations in the genes which are involved in the nephrotic syndrome viz. NPHS1, NPHS2, 
ACTN4, CD2AP and WT1, TRPC6, LAMB2 (coding for proteins like nephrin, podocin, α-
actinin-4, an adapter protein anchoring CD2 and others), have been found in two third of the 
patients with FSGS who present in the first year of life
74
. It has been found that the mutations 
in nephrin and podocin are the most frequent causative mutations of FSGS compared to 
defects in other podocyte specific genes. Disruption or dysregulation of signaling through 
these genes leads to foot process effacement, loss of podocytes and glomerulosclerosis
61
. 
 
Pathogenesis of glomerulosclerosis  
Glomerulosclerosis is the scarring (sclerosis) of the glomeruli. It is caused by activation of the 
glomerular cells to produce scar material. This is stimulated by the factors which are either 
produced by these cells themselves or are brought to the glomerulus by circulating blood 
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which enters the glomerular filter
75
. Podocyte loss through apoptosis or detachment into 
urinary space is a central determinant of progression to glomerulosclerosis
76,77
. Accordingly, 
experiments have shown that replacement of podocytes (either recovery or repair) contributes 
to the regression of glomerulosclerosis
78,79
. 
There have been many evidences in recent years indicating that the epithelial cells lining the 
Bowman´s capsule, called parietal epithelial cells, plays an important role in scaring. They 
undergo proliferation; produce extracellular matrix molecules like fibronectin, collagen as 
well as some other profibrotic growth factors
80
. They also produce chemokines like MCP-1, 
MIP-1 and IL-8 and therefore direct the leukocyte infiltration in the injured glomerulus
81
. 
 
1.2.3 Mechanisms of Podocyte death 
How does the glomerular epithelial sheath compensate for podocyte injury? Generally, 
differentiated podocytes cannot complete mitotic cell divisions by cytokinesis because this 
would require to completely reorganizing their actin cytoskeleton which is not compatible 
with maintaining secondary foot processes and the slit membrane
82
. But, as a mechanism of 
compensatory growth, they can enter the S-phase of the cell cycle for enhanced DNA 
synthesis to undergo hypertrophy
82,83
. The p53-dependent induction of cyclin kinase inhibitors 
such as p21 protects podocytes from passing the cell cycle restriction point of the G2/M phase 
which otherwise would lead to a process named “mitotic catastrophe”84-88. Mitotic catastrophe 
is defined as “cell death during mitosis” by an incomplete assembly of the chromosomes and 
the mitotic spindle in the pro-metaphase which then leads to aberrant chromosome 
segregation
87
. Such cells die either immediately within mitosis or shortly after via apoptosis 
or necrosis
89
. Morphologic features of mitotic catastrophe include multiple nuclei, 
micronuclei or irregularly shaped nuclei
85,87
. 
However, damaged podocytes also produce tumor necrosis factor (TNF)-α which triggers 
podocyte loss and progressive glomerulosclerosis by activating the extrinsic apoptosis 
pathway
90
. Environmental factors that activate glomerular macrophages in-situ to secrete 
TNF-α enhance this mechanism91-94 which can be blocked with etanercept to prevent TNF-α 
induced podocyte apoptosis and the progression of experimental CKD
90
. Thus, the relative 
contribution of apoptosis versus mitotic death to podocyte loss is not known. 
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1.2.4 Inflammation in FSGS 
An inflammatory response follows after tissue injury, irrespective of the underlying cause, 
leading to either tissue repair or progressive fibrosis with a loss of function
95
. The earlier 
stages of FSGS are characterized by a glomerular damage in conjunction with heavy 
proteinuria which then extends to a prominent tubulointerstitial injury. The later phase is 
associated with tubular atrophy, vacuolization and fibrosis (Figure 3). There is a marked 
mononuclear inflammatory cell infiltration (neutrophils, macrophages, mast cells, 
lymphocytes and dendritic cells etc.) in either phase of the disease
96,97
 (Figure 4). Both renal 
and systemic levels of the inflammatory cytokines (IL-1, IL-6, IL-8, TNF-α, MCP-1 etc.) are 
also increased
96,98
. 
 
NF-κB and FSGS 
The NF-κB transcription factors are one of the major regulators of the pro-inflammatory gene 
expression. Synthesis of cytokines like IL-1β, IL-6, IL-18, and TNF-α is mediated by NF-
κB99. The activation of NF-κB has pathogenic roles in vivo. Rangan GK et. al. have 
demonstrated that the renal expression of NF-κB increases progressively up to four weeks 
after adriamycin injections. They further demonstrate that this increase was correlated with 
the degree of proteinuria, inflammatory cells infiltrates and tubular atrophy
100
. These authors 
along with many others have shown that inhibition of NF-κB protected kidneys from 
adriamycin induced FSGS
100,101
. It has also been observed that the renal cortical and tubular 
cell CC chemokines, including MCP-1, RANTES, and MIP-1α were up-regulated via 
mediation of NF-κB, and contributed to FSGS by attracting inflammatory cells into the 
interstitium
102
. Blockade of the CC chemokine receptor, CCR1 substantially reduced 
interstitial leukocyte accumulation and the subsequent renal fibrosis in murine model of 
FSGS
97
. Therefore, in conclusion, the activation of NF-κB has an important role in mediating 
interstitial monocyte infiltration and tubular injury in nonimmune proteinuric tubulointerstitial 
inflammation. 
 
Leukocytes and FSGS 
Several studies have demonstrated that the infiltrating leukocytes, mainly macrophages and T 
cells play a pivotal role in the pathogenesis of FSGS
103-105
. Macrophages have heterogeneous 
phenotypes; subpopulations of macrophages (M1), known as `classical macrophages´, have 
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pathogenic function in renal inflammation and other M2 macrophage subpopulation, known 
as `alternative macrophages´ have renoprotective function in resolution of inflammation and 
renal repair after injury
106
.  
To study the influence of macrophages on FSGS, Wang et. al. have isolated macrophages 
from spleens of Balb/c mice and transformed them into M1 and M2 phenotype by treatment 
with either LPS or IL-4, IL-13 respectively, before infusing them into mice with FSGS. They 
have observed that, mice infused with M1 macrophages exhibited aggravated FSGS whereas 
mice infused with M2 macrophages were protected from FSGS
94
. In other independent 
studies, researchers have induced M2 macrophages in-vivo using cytokines like IL-25 and 
have shown that the phenotype change of macrophages from M1 to M2 protected the kidneys 
from adriamycin induced FSGS
103
.  It has also been observed that M2 macrophages induced 
the regulatory T cells in the lymph nodes draining the kidneys in adriamycin nephropathy 
(AN), which protected kidneys from FSGS
104
. Further, Wang et. al. have recently found that 
these protective regulatory T cells in AN express CD39, an ecto-enzyme that degrades 
extracellular nucleotides, such as ATP, which is essential for the protective function of 
regulatory T cells during adriamycin induced FSGS
105
. 
 
Complement system and FSGS 
The role of complement system in renal diseases has long been recognized. Complement 
system is critical in mediating not only host defense but also tissue injury, both in glomerulus 
and tubulointerstitium. Complement is activated as a result of proteinuria and contributes to 
fibrosis, scarring and progressive kidney disease. Irrespective of the pathways of complement 
activation in different diseases, the downstream injury is mainly mediated by C5 activation, a 
common mechanism in disease pathogenesis
107
. 
Several recent in-vivo studies have demonstrated that the intact alternative pathway of 
complement and its activation is critical for the progression of FSGS
108,109
. They observed 
that mice deficient in complement component of alternative pathway for e.g C3, factor D are 
protected from adriamycin induced FSGS
109
. Moreover, an inhibitory monoclonal antibody to 
factor B, another component of alternative pathway, delayed the development of adriamycin 
induced renal injury
108
. On the other hand, mice deficient in C1q and CD59 complement 
components of the classical pathway, developed similar or aggravated disease compared to 
the wild-type mice
109
. 
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1.2.5 Adriamycin nephropathy: a model of FSGS 
Adriamycin nephropathy (AN) is a well-established animal model, which is analogous to 
human FSGS. This model has enabled a greater understanding of the processes underlying 
FSGS. The successful induction of this model depends on the species, strain, gender and age 
of the animals as well as on source and batch of adriamycin. The Balb/c mice are highly 
susceptible to AN whereas C57BL/6 mice are highly resistant. This strain specific 
susceptibility has been linked to the single gene locus with recessive inheritance on 
chromosome 16
110
. The susceptibility alleles at this locus are associated with blunted 
expression of protein arginine methyltransferase on chromosome 8, a protein implicated in 
cellular sensitivity to chemotherapeutic agents
110
.  
Adriamycin, an anthracyclin antibiotic, is one of the most important anticancer agents. It is a 
DNA intercalating agent, which inhibits the enzyme topoisomerase II and thereby generates 
free radicals, which induce DNA damage and subsequent cell death
111
. Studies have shown 
that adriamycin induces cell death by two mechanisms depending on the concentration used. 
For example, at high doses it induces cell death by apoptosis and at low doses by mitotic 
catastrophe
112
, where cells with significant DNA damage undergo mitosis but are unable to 
complete it. Thus, when administered intravenously at an optimum concentration, adriamycin 
induces injury by direct toxic damage to the glomerulus. This direct damage to the kidney by 
adriamycin have been validated by clamping of a renal artery of one kidney before 
adriamycin injection. It was observed that, this procedure protected the clamped kidney from 
adriamycin induced FSGS
113
.  
Adriamycin causes thinning of glomerular endothelium and podocyte effacement associated 
with loss of barrier to filtration of plasma proteins in urine (proteinuria), occurring as early as 
one week after adriamycin injection and becomes severe by four weeks
114
. The histological 
changes show podocyte fusion, focal segmental and global glomerulosclerosis
115
 (Figure 3A-
3F), followed by tubulointerstitial injury (Figure 3H-3K).  This is associated with a severe 
glomerular as well as tubulointerstitial inflammation as seen by marked increase in T and B 
lymphocytes and macrophages in the kidneys
110,115
 (Figure 4). Adriamycin is known to 
activate NF-κB through IκB specific kinase (IKK) complex which regulates the pro-
inflammatory gene expression
116
. 
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Figure 3 Pathogenesis of FSGS A,B,C: Electron micrographs of glomeruli. A. Podocyte foot processes are 
normal in control mice. B. Two weeks after adriamycin injection they become fused. C. Six weeks after 
adriamycin injection they disappear. Black arrow represents foot processes and white arrows represent denuded 
basement membrane. (These images are adapted from Lee WV et. al.
110
). D,E,F : PAS staining of glomerular 
lesions. D. Control mouse showing no lesions. E. Glomeruli showing segmental lesions. F. Glomeruli showing 
global lesions. H & I. PAS staining of tubular injury. Tubules get damaged as early as week 2 after adriamycin 
injection. H. Damages tubular containing either urine or protein casts. I. A damaged nephron from a damaged 
glomerulus. J & K. PAS staining of tubular injury.  Tubular atrophy and increased protein or urine casts occur in 
the kidney four weeks after adriamycin injection. J. Lower magnification image representing the extent of 
tubular damage with proteinuria at week 4. K. Higher magnification image showing a globally sclerosed 
glomerulus surrounded by a necrotic tubule also containing protein or urine casts. 
 
 
Figure 4 Inflammation in FSGS Adriamycin treated kidney shows accumulation of A. CD45+ Leukocytes 
(image taken from Vielhauer V. et. al.
97
) B. CD3+ T lymphocytes C. F4/80 Macrophages after adriamycin 
injections. 
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Pros and cons of AN as an experimental model of CKD 
AN has several strengths as an model of CKD, viz
110
. 
1. It is highly reproducible and robust model of renal injury, with severe degree of tissue 
injury associated with acceptable mortality (< 5%) and morbidity (weight loss). 
2. The timing of the injury is consistent and predictable making it a best suited model to 
study the interventions which either protect or worsen the kidney injury. 
3. The nature of injury is exactly similar to the chronic proteinuric renal disease in 
humans. 
 
There are also limitations to use this model, viz
110
. 
1. Adriamycin has a narrow therapeutic index whereby doses as little as ±0.5mg/kg 
results in either no injury or toxicity leading to death. 
2. Batch-to-batch variability occurs whereby certain batches of adriamycin cause less 
severe injury than others. 
 
1.3. Murine Double Minute (MDM)-2 
Murine double minute (MDM)-2 is an intracellular protein with oncoprotein functions. It was 
originally identified in a spontaneously transformed mouse Balb/c cell line (T3T-DM)
117
. 
Later it was shown to interact with p53 and inhibit its transcription
118
. Since then MDM2 has 
evolved as a potential target for anticancer therapy. 
 
MDM2 is considered to be a valuable for a variety of reasons: 
1. MDM2 is an E3 ubiquitin ligase that negatively regulates p53 mainly by ubiquitin-
mediated degradation, thereby suppressing coordinated cell cycle arrest or apoptosis 
and promoting cell survival and growth
119
. 
2. Cell type-specific deletion of MDM2 recovers p53 and induces cell type-specific cell 
death
120
. 
3.  MDM2 is strongly expressed in many malignancies with wild-type p53 as an alternate 
mechanism to disrupt the p53 pathway in early cancer development
121,122
.  
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Figure 5 Regulation of p53 by MDM2 p53 and MDM2 form an auto-regulatory feedback loop. p53 expression 
is increased upon DNA damage by oxidative or genotoxic stress, which in turn increase the expression of 
MDM2.  MDM2 negatively regulates p53 in at least three different ways, i.e. (1) MDM2 functions as the E3 
ubiquitin ligase promoting ubiquitin-dependent proteosomal degradation of p53, (2) MDM2 facilitates nuclear 
export of p53 into the cell cytoplasm, moving p53 away from its site of action and (3) MDM2 interacts with p53 
transcription activation domain, thus inhibiting p53 transcriptional activity.   
 
 
4. MDM2 overexpression is linked to gain-of-function mutations in many tumors119. 
5. MDM2 blockade with suitable antagonists was shown to block tumor growth in a 
number of animal models
123
.  
 
As such a clinical trial is currently ongoing to study the effects of the MDM2 antagonist 
RO5503781, in advanced malignancies other than leukemia (www.clinicaltrials.gov). 
 
MDM2 has emerged as a valuable therapeutic target mainly because of the auto-regulatory 
feedback loop between p53 and MDM2 in various tumor cells
123
. However, recent data have 
shown that MDM2 has a number of p53-independent effects
124
. The p53 dependent and p53 
independent actions of MDM2 are discussed below. 
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1.3.1 The classical p53-dependent role of MDM2 on cell cycle control   
MDM2 is an oncoprotein, which negatively regulates tumor suppressor protein p53. p53 is 
one of the central regulators of cell cycle. It is activated upon cellular or genotoxic stress 
leading to quiescence, senescence or death of cells with DNA damage, therefore avoiding 
aberrant mitosis and carcinogenesis. Once activated p53 accumulates in the nucleus and being 
a transcription factor, it activates many genes specific for above mentioned functions of p53.  
At the same time, p53 also stimulates the expression of MDM2
125
. 
Activated MDM2 inhibits functions of p53 by three main pathways
125
: (Figure 5) 
1. It blocks transcriptional activity of p53 
2. It favors nuclear export of p53 
3. Being an E3 ubiquitin ligase, it stimulated degradation of p53 
 
This is how MDM2 and p53 form a tightly regulated negative feedback loop in which 
activated p53 up-regulates MDM2 expression which in turn will target p53 for degradation
125-
127
. 
This regulation of p53 by MDM2 in normal tissues is very essential, since p53 over-
expression results in dramatic apoptosis in multiple organs
128
. Moreover, MDM2 deficiency 
leads to p53-driven, uncontrolled cell death already during embryonic development. This 
phenotype can be entirely rescued by concomitant deletion of p53
129
. On the other side, 
MDM2 gene duplication or hyperactivation eliminates p53-mediated growth control of cells 
with significant DNA damage, which supports tumorigenesis
127
. Upon genotoxic or cytotoxic 
stress p53 and MDM2 are activated by phosphorylation and acetylation on specific sites 
resulting in their dissociation, p53 stabilization and consequent transcriptional up-regulation 
of p53 target genes leading to cell cycle arrest, DNA repair or apoptosis
130
. 
The interactions between MDM2 and p53 are affected by several other factors as well. For 
example, DNA damage activates ARF which binds to MDM2 and inhibits MDM2-mediated 
ubiquitination and degradation of p53, leading to stabilization of p53
131
. Some ribosomal 
proteins induced after ribosomal stress acts in the same manner
132
. 
Interestingly, MDM2 can also promote p53 mRNA translation thereby acting as a p53 
enhancer rather than p53 inhibitor
133
. 
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1.3.2 p53-independent roles of MDM2 in carcinogenesis 
There is growing evidence that MDM2 has a number of p53-independent functions in cell 
cycle regulation, differentiation, transcription, or DNA synthesis
124,126
. Many of these p53-
independent MDM2 roles foster cell transformation and tumorigenesis. MDM2 has been 
found to be overexpressed in tumors expressing both wild type and mutated p53
121,127
. This 
suggests that up-regulated MDM2 on its own has an additional growth advantages 
independent of p53. 
For example, estrogen-induced breast cancer cell proliferation requires a p53-independent 
MDM2-mediated pathway to activate cell proliferation and p53 is not the key target of 
MDM2
134
.  MDM2 also interacts with Rb, E2F1, MTBP, Smads etc. that play a key role in 
cell cycle regulation and seem to contribute to MDM2`s oncogenic effects independently of 
p53
124,126
. Furthermore, p53 is also not required for MDM2 to promote the translation of the 
anti-apoptotic protein XIAP which accumulates in cancer cells and supports their resistance to 
radiation therapy
135
. Interestingly, there is a report, which demonstrates tumor suppressive 
properties of MDM2. They document that the p53/Mdm2-double deficient mice had shorter 
tumor latency compared to p53-null mice with MDM2 expression retained
136
.  
MDM2 promotes cancer cell mobility via protein-protein interaction with non-metastatic cells 
2 protein (NME2). MDM2 overexpression suppresses NME2-mediated inhibition of cell 
motility
137
. MDM2 is also known to negatively regulate IGF1-R which protects cells from 
DNA-damage-induced apoptosis thus allowing transformed cells to undergo apoptosis, 
independent of p53
138
. 
 
Together, p53-dependent and -independent effects of MDM2 mostly promote the proliferation 
of cells with DNA damage, tumor growth, and metastasis. 
 
1.3.3 Inhibitors of p53-MDM2 interactions 
Restoring p53 activity by inhibiting the interaction between p53 and MDM2 represents an 
attractive approach for cancer therapy. Two classes of MDM2 antagonists have been reported, 
low molecular weight compounds and small peptides. To date, the most studied chemotypes 
amongst the low molecular weight compounds have been cis-imidazolines (e.g., nutlins), 
benzodiazepines (BDPs) and spiro-oxindoles
139
. The cis-imidazolines (nutlins-1, 2 and 3) are 
the first to be reported as potent and selective small molecular inhibitors of p53-MDM2 
Introduction   21 
 
interaction
139
. Nutlin-3 is the most potent amongst all. It is a racemic mixture of nutlin-3a 
(active enantiomer) and nutlin-3b (inactive enantiomer). 
The crystal structure based analysis revealed that a relatively deep p53 binding pocket is 
present on the surface of MDM2 and nutlins bind to this pocket competing with p53 and thus 
inhibiting MDM2 mediated degradation of p53
140
. Among all of the available inhibitors of 
p53-MDM2 interactions only nutlin-3 and MI-219 have excellent pharmacokinetic profile. A 
detailed analysis of pharmacokinetics of nutlin-3a has been performed in mice after both 
intravenous and oral administration. This study demonstrated that nutlin-3a shows rapid 
absorption, high bioavailability and saturable elimination kinetics
141
.  
 
1.3.4 Toxicity of MDM2 inhibitors to normal tissue 
One critical concern in the development of MDM2 inhibitors is their potential toxicity to 
normal tissues. This concern was intensified after the study which showed that p53-MDM2 
interactions are important in normal cells as well. Moreover, p53 activation in the absence of 
the MDM2 gene causes severe toxicity to radiosensitive normal adult mouse tissues, leading 
to rapid animal death
128
. However, nutlin-3a and MI-219 showed little toxicity to animals at 
therapeutically efficacious dose regimen
142
. 
 
1.4. Role of proliferation in kidney injury and repair 
1.4.1 Role of proliferation in AKI 
As mentioned earlier cell proliferation balances the loss of tubular cells by cell death after 
acute kidney injury (Figure 1A, 1D). Upon injury tubular cells start dividing at increased rate 
to replace the damaged tissue
42
. Thus, a rapid proliferative response ultimately leading to 
restoration of normal structure and function of the nephron is the cellular hallmark of kidney 
repair
44
. The origin of the cells that replace the injured tubular epithelia is not known, though 
several reports suggest the intra-renal origin
44,143
.  
Humphreys et. al. had generated transgenic mice, using genetic fate mapping technique, in 
which 94%–95% of tubular epithelial cells, but no interstitial cells, were labeled with either b-
galactosidase (lacZ) or red fluorescent protein (RFP). They observed that, two days after IRI, 
50.5% of outer medullary epithelial cells co-express Ki-67 and RFP, indicating that 
differentiated epithelial cells that survived injury undergo proliferative expansion
44
. They also 
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observed that after complete recovery, 66.9% of epithelial cells had incorporated BrdU, 
compared to only 3.5% of cells in the uninjured kidney
44
. In a very similar approach, Lin et. 
al. have produced transgenic mice that expressed enhanced GFP (EGFP) specifically and 
permanently in mature renal tubular epithelial cells. They also observed that, following IRI, 
EGFP-positive cells showed incorporation of BrdU and expression of vimentin
143
. Both of 
these studies strongly support the idea that the surviving tubular epithelial cells after the 
injury undergo proliferation or regeneration to replace the injured tubular epithelial cells after 
AKI in the adult mammalian kidney. 
Before confirmation of the above described mechanism of renal repair, several lines of reports 
suggested that the bone marrow derived cells or hematopoietic stem cells differentiate into 
tubular epithelial cells and undergo proliferation to replace the injured tubular epithelial 
cells
45,46
. Lin et. al. transplanted hematopoietic stem cells that express beta galactosidase 
constitutively from male mice into female mice which underwent IRI. Four weeks after HSC 
transplantation, beta-galactosidase-positive cells (male origin) were detected in renal tubules 
of the recipients by X-Gal staining (female mice)
46
. In another study, Kale et. al. 
demonstrated that Lin
–
Sca-1
+
 cells from the adult mouse bone marrow are mobilized into the 
circulation by transient renal ischemia and home specifically to injured regions of the renal 
tubule. There they differentiate into tubular epithelial cells and proliferate to replace the 
injured epithelial cells. Post-recovery analyses in these mice revealed that majority of the new 
cells in the necrotic tubules are derived from Lin
–
Sca-1
+
 cells
45
. Even though the current 
literature rules out the direct involvement of these cells in renal regeneration, it is noteworthy 
that there are some paracrine interactions between these cells and renal epithelial cells which 
in turn stimulate renal cell proliferation and thus regeneration after injury
144
. 
There are also evidences for the involvement of renal progenitor cells in the tubular 
regeneration
145
. Maeshima et. al. have demonstrated that the BrdU label retaining cells (LRC) 
undergo asymmetrical cell division after kidney injury and most of them become positive for 
proliferating cell nuclear antigen (PCNA), whilst the PCNA-positive but BrdU-negative 
tubular cells are rarely observed, suggesting that cells proliferating during tubular 
regeneration are essentially derived from LRC
145
. In a recent study, Angelotti ML et. al. have 
demonstrated that a new renal progenitor cell type, characterized as CD133
+
CD24
+
CD106
-
, 
have the capacity to undergo proliferation and replace the injured tubular epithelial cells after 
AKI
49
. These reports suggest that renal progenitor cells actively proliferate and eventually 
differentiate into epithelial cell, during tubular regeneration. 
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Figure 6 Role of proliferation in glomerulosclerosis A,B. Aberrant proliferation of glomerular epithelial stem 
cells  generates hyperplastic lesions. A. After massive podocyte injury, glomerular epithelial stem cells (red) 
generate cell bridges with the glomerular tuft in several areas of the glomerulus to quickly replace lost podocytes 
(light blue). However, numerous areas of podocyte injury distort glomerular structural integrity, thus altering the 
polarity of glomerular epithelial stem cell division and initiating their abnormal proliferation and the 
development of extracapillary hyperplastic lesions as well as crescents. Macrophages (green) can also be 
included within the lesions. Similar processes might occur in crescentic glomerulonephritis and collapsing 
glomerulopathy. B. Replacement of podocytes under physiologic conditions follows a gradient, with neo-
podocytes progressively added at the vascular stalk. Thus, the tip podocytes represent the “oldest” podocytes of 
the glomerular tuft, which suggests they might be more susceptible to injury related to heavy proteinuria. 
Glomerular epithelial stem cells may also proliferate and migrate from the urinary pole of the Bowman's capsule 
toward the tuft in an attempt to replace the podocytes lost in response to heavy proteinuria, and generate the tip 
lesion. (The images were adapted from Lasagni L et. al.
146
).  C,D. Aberrant proliferation of parietal epithelial 
cells generate hyperplastic lesions. C. Proliferation of PEC adjacent to the bridging podocytes, filling up 
Bowman’s space, giving the appearance of a cellular FSGS lesion. D. The proliferating PEC in Bowman’s space 
produces ECM (gray) that eventually forms tuft adhesions. (The images were adapted from Smeets B et. al.
73
). 
 
1.4.2 Role of proliferation in CKD 
The outcome of glomerular disorders depends on a balance between injury and regeneration 
executed by renal progenitors, bone marrow-derived stem cells, mesenchymal stem cells as 
well as parietal epithelial cells
146,147
. Although primary injury to each of the somatic cell types 
in the glomerular tuft associates with some form of glomerular disease, injury to endothelial 
and mesangial cells repair by proliferation of adjacent cells
146
.  
On the other hand, as mentioned earlier podocytes are highly differentiated cells that cannot 
divide, which explains why podocyte injury results in focal or global glomerulosclerosis. Data 
from experimental models demonstrate that podocyte repopulation contributes to the 
regression of glomerulosclerosis
78
. Since resident podocytes do not divide, this suggests that 
new podocytes are derived by regeneration from glomerular epithelial stem cells. A large 
body of evidence has recently suggested that parietal epithelial cells represent a reservoir of 
renal progenitors in adult human kidney which generate novel podocytes during childhood 
and adolescence, and can regenerate injured podocytes
147
. 
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However, this regenerative process is often inadequate because of inefficient proliferative 
responses by glomerular epithelial stem cells or renal progenitors with aging or in the setting 
of focal segmental glomerulosclerosis, resulting in inadequate or no repair of podocytes after 
injury and subsequent glomerulosclerosis
146
 (Figure 6A,6B). Alternatively, an abnormal 
proliferative response of these cells to podocyte injury can generate hyperplastic glomerular 
lesions as observed in crescentic glomerulonephritis, collapsing glomerulopathy and other 
types of glomerular disorders
146,147
 (Figure 6C, 6D). 
The later phenomenon has been investigated in detail by Smeet et. al.. They studied the 
development of FSGS in Thy-1.1 transgenic mice. Injection of anti-Thy-1.1 monoclonal 
antibody to these mice induced acute albuminuria and FSGS lesions. They found that at day 3 
after the anti-Thy-1.1 mAb injection, podocyte became hypertrophic and they formed bridges 
to PEC and against denuded segments of Bowman's capsule. Further, at day 6 they observed a 
marked proliferation in the bowman’s space. These proliferating cells were negative for 
desmin and all podocyte markers, but stained positive for CD10, and thus confirmed to be 
PECs. Moreover, the staining properties of the early adhesions were found to be identical to 
that of Bowman's capsule, suggesting that the ECM in the adhesions was produced by PECs
73
. 
Therefore, it had been confirmed that the PECs proliferate and produce ECM and contribute 
to the development of glomerulosclerosis. 
 
In summary, proliferation of renal cells (both tubular and glomerular) is essential process for 
renal repair after injury. Therefore it is necessary to investigate the processes, molecules, 
pathways which promote the recovery/repair or which suppress the injury.  MDM2, an 
oncoprotein, participates in cell proliferation by keeping p53 under control. It has been found 
to be overexpressed in the cancer tissue. So far, the involvement of MDM2 in renal injury and 
repair has not been studied in detail. The scope of the thesis is to study the roles of MDM2 in 
renal injury and repair. 
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2. Hypotheses 
Based on the above literature, it was hypothesized that MDM2 plays an important role in both 
acute as well as chronic renal injury. 
 
 Acute kidney injury 
It was hypothesized that the regulatory role of MDM2 on p53 is mandatory for limiting p53-
dependent tubular cell apoptosis and for promoting tubular cell regeneration during AKI. As 
such the assumption was that therapeutic MDM2 inhibition, with nutlin-3a, will aggravate 
acute tubular necrosis and impair tubular regeneration in AKI, a theoretical concern that have 
been addressed by studying the effects of the MDM2 antagonist nutlin-3a in a model of 
murine postischemic AKI. 
 
Chronic kidney disease  
Podocytes strongly express MDM2. Therefore, it was hypothesized that MDM2 is essential 
for podocyte survival and it also promotes the abnormal healing response that contribute to 
glomerulosclerosis after podocyte injury. This has been addressed by studying the effects of 
the MDM2 antagonist, nutlin-3a, in a murine model of adriamycin induced focal segmental 
glomerulosclerosis. The assumption was that MDM2 inhibition will aggravate AN by 
enhancing podocyte apoptosis. 
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3. Material and Methods 
3.1 Instruments and Chemicals 
3.1.1 Instruments 
Balance:  
Analytic Balance, BP 110 S Sartorius, Göttingen, Germany 
Mettler PJ 3000 Mettler-Toledo, Greifensee, Switzerland 
 
Cell Incubators: 
 
Type B5060 EC-CO2 Heraeus Sepatech, München, Germany 
 
Centrifuges: 
 
Heraeus, Minifuge T VWR International, Darmstadt, Germany 
Heraeus, Biofuge primo Kendro Laboratory Products GmbH, Hanau, 
Germany 
Heraeus, Sepatech Biofuge A Heraeus Sepatech, München, Germany 
 
ELISA-Reader: 
 
Tecan, GENios Plus Tecan, Crailsheim, Germany 
 
Fluorescence Microscopes: 
 
Leica DC 300F Leica Microsystems, Cambridge, UK 
Olympus BX50 Olympus Microscopy, Hamburg, Germany 
 
Spectrophotometer: 
 
Beckman DU® 530 Beckman Coulter, Fullerton, CA, USA 
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TaqMan Sequence Detection 
System: 
ABI prism ™ 7700 sequence 
detector 
PE Biosystems, Weiterstadt, Germany 
 
Other Equipments: 
 
Nanodrop PEQLAB Biotechnology GMBH, Erlangen, Germany 
Cryostat RM2155 Leica Microsystems, Bensheim, Germany 
Cryostat CM 3000 Leica Microsystems, Bensheim, Germany 
Homogenizer ULTRA-TURRAX 
T25 
IKA GmbH, Staufen, Germany 
Microtome HM 340E Microm, Heidelberg, Germany 
pH meter WTW WTW GmbH, Weilheim, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Vortex Genie 2™ Bender & Hobein AG, Zürich, Switzerland 
Water bath HI 1210 Leica Microsystems, Bensheim, Germany 
 
3.1.2 Chemicals and reagents 
RNeasy Mini Kit Qiagen GmbH, Hilden, Germany 
RT-PCR primers PE Biosystems, Weiterstadt, Germany 
 
Cell culture: 
 
DMEM-medium Biochrom KG, Berlin, Germany 
RPMI-1640 medium GIBCO/Invitrogen, Paisley, Scotland, UK 
FSC Biochrom KG, Berlin, Germany 
Dulbecco’s PBS (1×) PAA Laboratories GmbH, Cölbe, Germany 
Trypsine/EDTA (1×) PAA Laboratories GmbH, Cölbe, Germany 
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Penicillin/Streptomycin (100×) PAA Laboratories GmbH, Cölbe, Germany 
 
Antibodies: 
 
MDM2 Abcam, Cambridge, UK 
p-MDM2 Cell signaling, Danvers, MA 
p53 Santa Cruz Biotechnology, Santa Cruz, CA 
p-p53 Cell signaling, Danvers, MA 
p21 Santa Cruz Biotechnology, Santa Cruz, CA 
NF-κB p65 Cell signaling, Danvers, MA 
NF-κB p-p65 Cell signaling, Danvers, MA 
p42/44 MAPK Cell signaling, Danvers, MA 
p-p42/44 MAPK Cell signaling, Danvers, MA 
p38 MAPK Cell signaling, Danvers, MA 
p-p38 MAPK Cell signaling, Danvers, MA 
H3 Cell signaling, Danvers, MA 
p-H3  
IκB Cell signaling, Danvers, MA 
p-IκB Cell signaling, Danvers, MA 
p52 Cell signaling, Danvers, MA 
HRP linked Anti-Rabbit secondary 
Ab 
Cell signaling, Danvers, MA 
HRP linked Anti-Mouse secondary 
Ab 
Cell signaling, Danvers, MA 
HRP linked Anti-Goat secondary Ab Dianova, Hamburg, Germany 
β-Actin Cell signaling, Danvers, MA 
α-tubulin Cell signaling, Danvers, MA 
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Tamm–Horsfall protein Santa Cruz Biotechnology, Santa Cruz, CA 
Lotus tetragonolobus lectin Vector Labs, Burlingame, CA 
rat anti-mouse neutrophils Serotec, Oxford, UK 
CD3+ AbD Serotec, Düsseldorf, Germany 
F4/80+ AbD Serotec, Düsseldorf, Germany 
Claudin Bioworld technology, CB8 7SY England 
Nephrin Acris Antibodies GmbH, Herford, Germany 
Ki-67 Dako Deutschland GmbH, Hamburg, Germany 
α-SMA Dako Deutschland GmbH, Hamburg, Germany 
 
Elisa Kits: 
 
mouse IL-6 R &D Systems, Minneapolis, MN, USA 
mouse TNF-α Biolegend, San Diego, CA 
mouse Albumin Bethyl Laboratories, TX, USA 
Creatinine FS DiaSys Diagnostic System, GmBH, Holzheim, 
Germany 
Urea FS DiaSys Diagnostic System, GmBH, Holzheim, 
Germany 
 
Chemicals: 
 
Acetone Merck, Darmstadt, Germany 
AEC Substrate Packing Biogenex, San Ramon, USA 
Bovines Serum Albumin Roche Diagnostics, Mannheim, Germany 
 Skim milk powder Merck, Darmstadt, Germany 
DEPC Fluka, Buchs, Switzerland 
DMSO Merck, Darmstadt, Germany 
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Diluent C for PKH26 dye Sigma-Aldrich Chemicals, Germany 
EDTA Calbiochem, SanDiego, USA 
30% Acrylamide Carl Roth GmbH, Karlsruhe, Germany 
TEMED Santa Cruz Biotechnology, Santa Cruz, CA 
Eosin Sigma, Deisenhofen, Germany 
Ethanol Merck, Darmstadt, Germany 
Formalin Merck, Darmstadt, Germany 
Hydroxyethyl cellulose Sigma-Aldrich, Steinheim, Germany 
HCl (5N) Merck, Darmstadt, Germany 
Isopropanol Merck, Darmstadt, Germany 
Calcium chloride Merck, Darmstadt, Germany 
Calcium dihydrogenphosphate Merck, Darmstadt, Germany 
Calcium hydroxide Merck, Darmstadt, Germany 
MACS-Buffer Miltenyl Biotec, Bergisch Gladbach, Germany 
Beta mercaptoethanol Roth, Karlsruhe, Germany 
Sodium acetate Merck, Darmstadt, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium citrate Merck, Darmstadt, Germany 
Sodium dihydrogenphosphate Merck, Darmstadt, Germany 
Penicillin Sigma, Deisenhofen, Germany 
Roti-Aqua-Phenol Carl Roth GmbH, Karlsruhe, Germany 
Streptomycin Sigma, Deisenhofen, Germany 
Tissue Freezing Medium Leica, Nussloch, Germany 
Trypan Blue Sigma, Deisenhofen, Germany 
Oxygenated water DAKO, Hamburg, Germany 
Xylol Merck, Darmstadt, Germany 
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Miscellaneous:  
Cell death detection (TUNEL) kit Roche, Mannheim, Germany 
Microbeads Miltenyl Biotech, Germany 
Cell Titer 96 Proliferation Assay  Promega, Mannheim, Germany 
LS+/VS+ Positive selection columns Miltenyl Biotec, Bergish Gladbach, Germany 
Preseparation Filters Miltenyl Biotec, Bergish Gladbach, Germany 
Super Frost® Plus microscope slides  Menzel-Gläser, Braunschweig, Germany 
Needles BD Drogheda, Ireland 
Pipette’s tip 1-1000μL Eppendorf, Hamburg, Germany 
Syringes Becton Dickinson GmbH, Heidelberg, Germany 
Plastic histocasettes NeoLab, Heidelberg, Germany 
Tissue culture dishes Ø 100x20mm TPP, Trasadingen, Switzerland 
Tissue culture dishes Ø 150x20mm TPP, Trasadingen, Switzerland 
Tissue culture dishes Ø 35x10mm Becton Dickinson, Franklin Lakes, NJ, USA 
Tissue culture flasks 150 cm2 TPP, Trasadingen, Switzerland 
Tubes 15 and 50 mL TPP, Trasadingen, Switzerland 
Tubes 1.5 and 2 mL TPP, Trasadingen, Switzerland  
All other reagents were of analytical grade and are commercially available from Invitrogen, 
SIGMA or ROTH. 
 
3.2 Experimental procedures 
 
3.2.1 Animals 
C57BL/6 wild-type mice and p53-deficient C57BL/6 mice were obtained from Taconic (Ry, 
Denmark) and Blab/c mice were obtained from Charles River (Sulzfeld, Germany). All mice 
were kept under normal housing conditions under a 12-h light and dark cycle. Water and 
standard chow (Ssniff, Soest, Germany) were available ad libitum for the complete duration 
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of the study. Cages, bedding, nestles, food, and water were sterilized by autoclaving before 
use.  
 
3.2.2 Animal models 
Ischemia Reperfusion induced Acute Renal Failure 
Renal ischemia–reperfusion was performed under general anesthesia. The left or both renal 
pedicles were clamped for either 45 or 30 min, respectively, with microaneurysm clamps 
(Medicon, Tuttlingen, Germany) via 1-cm flank incisions. Body temperature was constantly 
measured with a rectal probe and maintained at 36–370C throughout the procedure by placing 
the mice on a heating pad (Figure 7). After clamp removal, the kidney was inspected for 
restoration of blood flow closing the wound with standard sutures. To maintain fluid balance, 
all mice were supplemented with 0.5 ml of normal saline. 
 
 
Figure 7 Ischemia reperfusion surgery on C57Bl6 mice 
 
Adriamycin induced Focal Segmental Glomerulosclerosis 
To induce progressive glomerulosclerosis and tubulointerstitial inflammation in mice 
adriamycin (Pharmacia & Upjohn, Erlangen, Germany) was injected intravenously at day 0 
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and day 14 at a dose of 13mg/kg body weight. AN is characterized by persistent proteinuria 
throughout the study period of 4 weeks, associated with chronic glomerular and 
tubulointerstitial lesions as seen in human FSGS. 
Mice from both the studies received intra-peritoneal injections with either 20 mg/kg of the 
MDM2 inhibitor nutlin-3a (Axxora, Lörrach, Germany) in 50% dimethyl sulfoxide (vehicle) 
or vehicle only. Five to eight mice per group were examined in each experiment. At the end of 
each experiment plasma and urine samples were collected before sacrifice by cervical 
dislocation and then afterwards kidney tissues was harvested. The harvested kidney tissues are 
divided into three parts each. One part was immediately flash frozen in liquid nitrogen and 
then further stored at -80
0
C for protein isolation and cryo sections, second part was collected 
in RNA later solution (Ambion, CA, USA) and stored at -20
0
C for RNA isolation and third 
part of the kidney was kept in formalin to fix the tissue before embedding in paraffin for 
histological analysis.  
All experimental procedures were performed according to the German animal care and ethics 
legislation and had been approved by the local government authorities. 
 
3.2.3 Experimental design 
Study 1: Ischemic renal failure 
Groups of C57Bl6 wild type mice (n=6) received single nutlin-3a injection 24 h before 
bilateral renal artery clamping for 45 min. Control mice received vehicle. All mice were then 
sacrificed 24 h after the IR surgery.  Next groups of C57Bl6 wild type mice (n=6) received 
nutlin-3a injection 24 h before bilateral renal artery clamping for 30 min. They received 
additional nutlin-3a injections at day +1 and +3 after the IR surgery.  Control mice received 
vehicle. These mice were sacrificed at day +5 after IR surgery. 
In another set of experiment, groups of mice (n=6) received a single nutlin-3a injection 24 h 
before unilateral renal artery clamping; others received three injections on the days -1, +2, and 
+3 after the IR surgery. All mice were sacrificed at day +5 after IR surgery. Similar set of 
experiments were performed in p53-deficient mice (Figure 8). 
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Figure 8 Schematics of experiment design for Ischemic reperfusion induced acute renal failure 
 
Study 2: Adriamycin nephropathy 
To study the role of MDM2 in glomerular injury in adriamycin induced FSGS, groups of 
Balb/c mice received single intravenous injections of adriamycin 13mg/kg at day 0 (week 0) 
and either nutlin-3a or vehicle at day 8, 10, 12 before sacrifice at day 14 (week 2).  
Another groups of Balb/c mice received two intravenous injections of adriamycin 13mg/kg at 
day 0 and day 14 (week2) and either nutlin-3a or vehicle on alternate days after the second 
adriamycin injection (week 2) till they were sacrificed at day 28 (week 4) for studying the role 
of MDM2 in tubulointerstital injury in FSGS (Figure 9). 
 
 
Figure 9 Schematics of experiment design for adriamycin induced chronic renal failure 
 
3.3 Blood and urine sample collection 
Blood samples were collected by retro-orbital bleeding technique, under isoflurane anesthesia, 
in microcentrifuge tubes containing EDTA (10μl of 0.5 M solution per 200μl of blood).  
Collected blood samples were centrifuged at 8000 rpm for 5 min and plasma was separated 
and stored at -20
0
C until used for analysis.  
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Urine samples were collected at the end of the study and are stored at -20
0
C until used for 
further biochemical analysis.  
 
3.4 Urinary albumin to creatinine ratio 
3.4.1 Urinary albumin 
Urinary albumin levels were determined using albumin Elisa kit from Bethyl laboratories 
following manufacturer’s instructions. Generally albumin levels in urine samples from FSGS 
mice were quite high, so urine samples were diluted 1000 to 1500 times with water before 
estimation. In short, capture antibody (Anti-Mouse albumin, 1:100 dilution) was coated on 
polyethylene flat bottom 96 well plates (Nunc plates) using carbonate-bicarbonate (pH 9.6) 
coating buffer. After overnight incubation of the capture antibody at 4
0
C, plate was washed 3 
times with wash buffer (Tris NaCl with Tween 20) and blocked with blocking solution (Tris, 
NaCl with 1% BSA, pH 8) at room temperature for 1 hour. After blocking was over the plate 
was washed 3 to 5 times with wash buffer and then diluted samples/standards were added in 
respective wells and further incubated for 1 hour. After incubation was over each well was 
washed 5 times with wash buffer and diluted HRP-conjugated detection antibody (using the 
suggested dilution) was added and the plate was incubated in dark for further 1 hour. After 
HRP-conjugate incubation was over each well was washed 5 to 7 times with wash buffer and 
TMB reagent (freshly prepared by mixing equal volumes of two substrate reagents) was 
added and incubated in dark till color reaction was completed followed by addition of stop 
solution (2 M H2SO4). The absorbance was read at 450 nm within 10 min of stop solution 
addition. The albumin content in each sample was determined using the equation of 
regression line generated by plotting absorbance of different standards against their known 
concentrations.  
 
3.4.2 Urinary creatinine, plasma creatinine and plasma BUN 
Urinary creatinine and plasma creatinine levels were measured using Jaffe´s enzymatic 
reaction using a Creatinine FS kit (DiaSys Diagnostic system, GmBH, Holzheim, Germany). 
Urine samples were diluted 10 times with distilled water whereas plasma samples were used 
undiluted. Different dilutions of standard were prepared using the stock provided with the kit. 
Working monoreagent was prepared by mixing 4 part of reagent 1 (R1) and 1 part of reagent 
2 (R2) provided with the kit. Then, 10 μl of each of the diluted samples and standards were 
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added to a 96 well plate with flat bottom (Nunc maxisorb plate). The monoreagent (200µl) 
was added to each well and the reaction mixture was incubated for one minute before 
measuring the absorbance  at 492 nm immediately after and 1 (A1) and 2 (A2) min of addition 
using elisa plate reader. The change in absorbance (Δ A) was calculated as Δ A = [(A2 – A1) 
sample or standard] – [(A2 – A1) blank]. And creatinine content of samples was calculated as: 
Creatinine (mg/dl) = ΔA sample /ΔA standard * Concentration of standard (mg/dl) 
Plasma BUN levels were measured using an enzymatic reaction using a Urea FS kit (DiaSys 
Diagnostic system, GmBH, Holzheim, Germany). Different dilutions of standard were 
prepared using the stock provided with the kit. Working monoreagent was prepared by mixing 
4 part of reagent 1 (R1) and 1 part of reagent 2 (R2) provided with the kit. Then, 2 μl of each 
of the sample and standards were added to a 96 well plate with flat bottom (Nunc maxisorb 
plate). The monoreagent (200µl) was added to each well and the reaction mixture was 
incubated for one minute before measuring the absorbance  at 360 nm immediately after and 1 
(A1) and 2 (A2) min of addition using elisa plate reader. The change in absorbance (Δ A) was 
calculated as Δ A = [(A1 – A2) sample or standard] – [(A1 – A2) blank]. And BUN content of 
samples was calculated as: 
BUN (mg/dl) = ΔA sample /ΔA standard * Concentration of standard (mg/dl)*0.467 
Urinary albumin to creatinine ratio was calculated after converting values for albumin and 
creatinine to similar units (mg/dl). Albumin content for each sample calculated (mg/dl) was 
divided by creatinine content (mg/dl) for the same sample. 
 
3.5 Cytokines Elisa 
All cytokine levels in supernatant collected from in-vitro cells stimulations were estimated 
using ELISA kits following the manufacturer’s instructions. In brief, The NUNC ELISA plate 
wells were captured overnight at 4°C with the capture antibody in coating buffer. Next day 
the plates were washed 3 times with the washing buffer as given in protocol for 3 times and 
blocked with the blocking solution or assay diluent for 1 hour or as specified. Again the 
washings were repeated 3 times followed by addition of standards; samples and sample 
diluent (blank) into the wells of tap dried plate and incubated at RT for 2 hours. This was 
followed by washings for 5 times or as specified. Then HRP/AP conjugated secondary 
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antibody diluted in assay diluent was added. Incubate the plate as specified. The wells were 
washed again for 5-7 times or as specified and incubated with the 100 μl of substrate A and B 
(1:1 mixture) for 25-30 min in dark to develop colour. The reaction was stopped by addition 
of 100 μl 1 M H2SO4. The reading of the absorbance was taken at 450 nm and the reference 
wavelength was 620 nm using a spectrophotometer (TECAN-Genios Plus). 
 
3.6 Immunostaining and Confocal imaging 
For immunohistological studies middle part of kidney from each mouse were fixed in 
formalin (10 % in PBS or Saline) over night and processed using tissue processors (Leica) and 
paraffin blocks were prepared. 2µm thick paraffin-embedded sections were cut. De-
paraffinization was carried out using xylene (3 * 5 min) followed by re-hydration, which was 
carried out by incubating the sections in 100% absolute ethanol (3 * 3 min), 95% ethanol (2 * 
3 min) and 70% ethanol (1 * 3 min) followed by washing with PBS (2 * 5 min). Blocking 
endogenous peroxidase was carried out by incubating sections in H2O2 and methanol mixture 
(20 ml of 30% H202 in 180ml of methanol) for 20 min in dark followed by washing in PBS 
(2* 5min). For unmasking of antigen sections were dipped in antigen unmasking solution (3 
ml of antigen unmasking solution + 300 ml of distilled water) and cooked in microwave for 
total of 10 min (4*2.5 min, every 2.5 min water level was checked and made up to the initial 
levels with distilled water every time). After microwave cooking sections were cooled to 
room temperature for 20 min and washed with PBS. Blocking endogenous biotin was carried 
out by incubating sections with one drop of Avidin (Vector) for 15 min followed by 
incubation with Biotin (Vector) for further 15 min. After the incubation was over sections 
were washed with PBS (2* 5 min). 
Sections were incubated with different primary antibodies either for 1 hour at room 
temperature or overnight at 4
0
C in a wet chamber followed by wash with PBS (2* 5 min). 
After washing sections were incubated with biotinylated secondary antibodies (1:300, dilution 
in PBS) for 30 min followed by wash with PBS (2* 5 min). Substrate solution (ABC solution, 
Vector) was added and sections were incubated for 30 min at room temperature in a wet 
chamber followed by wash with PBS (1* 5 min). Tris (1* 5 min) and sections were stained for 
DAB followed by counter staining with methyl green (Fluka). Then sections were washed 
with alcohol (96 %) to remove excess stain and xylene. Sections were dried and mounted with 
VectaMount (Vector). 
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The primary antibodies used in the study are mentioned above. For each immunostaining 
negative controls staining was performed by incubation with a respective isotype antibody 
instead of primary antibody. 
For Confocal imaging, the sections, prepared as described above, were incubated with the 
following primary antibodies: pig anti-mouse nephrin (1:100, Acris Antibodies, Herford, 
Germany), rabbit anti-mouse WT1 (1:25, Santa Cruz Biotechnology, Santa Cruz, CA) and 
rabbit anti-mouse MDM2 (1:100, Abcam, Cambridge, UK) and Biotinylated lotus 
tetragonolobus lectin (Vector Labs, CA, USA) for 1 h in PBS or 0.1% milk solution in room 
temperature. After washing, the sections were incubated with secondary antibodies guinea pig 
Alexa Fluor 488 (1:100, Invitrogen, Carlsbad, CA) or rabbit Cy3 (1:200, Jackson 
ImmunoResearch Laboratories, West Grove, PA) for 30 minutes at room temperature. 
Stainings were evaluated using confocal microscopy with LSM 510 microscope and LSM 
software (Carl Zeiss AG). 
 
3.7 Periodic acid Schiff staining 
Formalin-fixed tissues were processed using tissue processors (Leica) and paraffin blocks 
were prepared. 2 µm thick paraffin-embedded sections were cut. De-paraffinization was 
carried out using xylene (3 * 5 min) followed by re-hydration by incubating the sections in 
100% absolute ethanol (3 * 3 min), 95% ethanol (2 * 3 min) and 70% ethanol (1 * 3 min) 
followed by washing with distilled water (2 * 5 min). Re-hydrated sections were incubated 
with Periodic acid (2 % in distilled water) for 5 min followed by washing with distilled water 
(1* 5 min). Then sections were incubated with Schiff solution for 20 min at room temperature 
followed by washing with tap water (1* 7 min) and counter staining with Hematoxylin 
solution (1* 2 min). This was followed by washing with tap water (1* 5 min) and finally 
sections were dipped in alcohol 90% and dried and closed with cover slips. 
 
3.8 Histopathological evaluations 
3.8.1 PAS staining 
Postischemic tubular injury was scored by assessing the percentage of tubules in the 
corticomedullary junction that displayed cell necrosis, loss of brush border, cast formation, 
and tubular dilatation as follows:  
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Score Injury level 
0 None 
1 ≤ 10% 
2 21 % to 40 % 
3 41 % to 60 % 
4 61 % to 80 % 
5 81 % to 100 % 
All sections were quantified in each group and were expressed as mean ± SEM. 
Glomerular sclerotic lesions were assessed using a semi quantitative score by a blinded 
observer as follows, after assessing 50 glomeruli from each section: 
Score Lesion in Glomeruli  
No lesion None 
Segmental Lesion ≤ 50 %  
Global Lesion ≥ 50 % 
All sections were quantified in each group and were expressed as percentage of glomeruli 
with each score (mean ± SEM). 
 
3.8.2 Mac2 staining 
Number of infiltrated macrophages in glomeruli as well as in interstitium were counted in 
sections stained with Mac2 (pan marker for macrophage) antibodies. Mac2 positive cells were 
counted manually in 15 glomeruli or 15 non-over lapping high power fields interstitium for 
each section and were presented as mean ± standard error of mean for respective groups. 
 
3.8.3 Ki67 staining 
Number of proliferating cells within glomeruli and tubules were evaluated using Ki 67 
staining. For quantification Ki67 positive cells were counted manually in 25 glomeruli in each 
section and for proliferating tubular cells, 10 h.p.f. from each section was calculated and 
presented as mean ± SEM for respective groups. 
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3.8.4 SMA-α staining 
For tissue fibrosis assessment sections were stained with SMA-α anti-body. Adobe photoshop 
software was used to quantify the percentage SMA-α positive area from each section. The 
data is presented as mean ± SEM for respective groups.  
 
3.8.5 TUNEL staining 
A terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was 
performed to quantify apoptotic tubular epithelial cells. Parrafin sections of kidney were 
stained with In situ Cell death detection kit (Roche, Mannheim, Germany) according to the 
manufacturer’s instruction. The TUNEL positive cells were counted using adobe photoshop 
software. The data is presented as mean ± SEM for respective groups. 
 
3.9 RNA analysis 
3.9.1 RNA isolation 
A part of kidney from each mouse was preserved in RNA-later immediately after kidney 
isolation and stored at -20
0
C until processed for RNA isolation. RNA isolation was carried out 
using RNA isolation kit from Ambion (Ambion, CA, USA). In short, tissues (30 mg) 
preserved in RNA-later were homogenized using blade homogenizer for 30 seconds at 4 in 
lysis buffer (600 μl) containing β-mercaptoethanol (10 μl/ml). The homogenate was 
centrifuged at 6000 rpm for 5 min and 350 μl of supernatant was transferred to fresh DEPC-
treated tube. To this equal amount (350 μl) of 70 % ethanol was added and mixed gently.  
This whole mixture was then loaded on RNA column and processed for RNA isolation as per 
the manufacturer’s instruction. Isolated RNA measured, checked for purity as follows and 
was stored at -80
0
C. 
 
3.9.2 RNA quantification and purity check 
The isolated RNA samples were quantified using Nano drop (PEQLAB Biotechnology 
GMBH, Erlangen, Germany). The ratio of optical densities at 260 nm and 280 nm is an 
indicator for RNA purity (indicative of protein contamination in the RNA samples). Only 
samples with a ratio of 1.8 or more were considered to be of acceptable quality. 
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Figure 10 RNA integrity check 
 
3.9.3 RNA integrity check 
Further quality check (if necessary) was performed using a denaturing RNA gel. In short 2 % 
Agarose gel with Ethidium-bromide was casted, RNA samples were mixed with RNA loading 
buffer (4:1 ratio) (Sigma Aldrich, Germany) and were loaded on the gel. Electrophoresis was 
carried out at constant volt (70-100 V) using MOBS running buffer for 1 hour and the gel was 
read on a gel documentation apparatus under UV lamp. RNA samples showing a single bright 
band were considered to be of good quality. Loss of RNA integrity could be detected as smear 
formation in the agarose gel (Figure 10). 
 
3.9.4 cDNA synthesis and real-time RT-PCR (SYBR Green) 
The isolated RNA samples were quantified and processed for cDNA conversion using reverse 
transcriptase II (Invitrogen, Karlsruhe, Germany). RNA samples were diluted in DEPC 
treated tubes with water to get final concentration of 2 μg / 30 μl, to this diluted RNA samples 
13.9 μl of master mix* was added, all tubes were incubated at 420C for 1 hour and 30 min on 
thermal shaker. Upon completion of incubation cDNA samples were stored at -20
0
C until 
used for RT-PCR analysis using SYBR green. The cDNA samples prepared as described 
above were diluted 1:10 a dilution for the real-time RT-PCR. 2 μl of diluted cDNA samples 
were mixed with SYBR green master mix (10 μl), forward primer, specific for gene of interest 
(0.6 μl), reverse primer specific for gene of interest (0.6 μl), Taq polymerase (0.16 μl) and 
distilled water (6.64 μl). The real-time RT-PCR was performed using Light Cycler480. 
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*The master mix was prepared by mixing 9 μl of 5x buffer (Invitrogen, Karlsruhe, Germany), 
1 μl of 25 mM dNTP mixture (Amersham Pharmacia Biotech, Freiburg, Germany), 2 μl of 0.1 
M DTT (Invitrogen, Karlsruhe, Germany), 1 μl of 40U/ μl RNAsin (Promega, Mannheim, 
Germany), 0.5 μl of Hexanucleotide (Roche, Mannheim, Germany), 1 μl of Superscript 
(Invitrogen, Karlsruhe, Germany) or ddH2O in the case of the control cDNA (RT minus).  
 
3.9.5 Real time PCR 
Pre-incubation was carried out for 5 minutes at 95
0
C so as to activate the polymerase and 
complete de-naturation of cDNA samples. Then the cDNA was amplified for 40 cycles, each 
comprising of 15 seconds incubation at 95
0
C and 45 seconds incubation at 60
0
C. For melting 
curve initial 95
0
C for 5 seconds followed by 65
0
C for 1 min with continuous heating was 
used. The RT-PCR for the reference genes (18S rRNA) was carried out under similar 
conditions. The CT values were calculated using the Light Cycler480 and the results were 
normalized with respective reference gene expression for each sample. In all cases controls 
consisting of ddH2O were negative for target or reference genes. All designed SYBR green 
primers for all genes evaluated were obtained from Metabion (Metabion, Martinsried, 
Germany). 
 
3.9.6 Oligonucleotide primers used for SYBR-Green RT-PCR 
The following oligonucleotide primers were used in the study. 
Gene Sequence 
18s Forward: GCAATTATTCCCCATGAACG 
Reverse: AGGGCCTCACTAAACCATCC 
Ccl2 Forward: CCTGCTGTTCACAGTTGCC 
Reverse: ATTGGGATCATCTTGCTGGT 
Cxcl10 Forward: GGCTGGTCACCTTTCAGAAG 
Reverse: ATGGATGGACAGCAGAGAGC 
IL-6 Forward: TGATGCACTTGCAGAAAACA 
Reverse: ACCAGAGGAAATTTTCAATAGGC 
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Nphs1 
(Nephrin) 
Forward: TTAGCAGACACGGACACAGG 
Reverse: CTCTTTCTACCGCCTCAACG 
Nphs2 
(Podocin) 
Forward: TGACGTTCCCTTTTTCCATC 
Reverse: CAGGAAGCAGATGTCCCAGT 
Nos2 
(iNos) 
Forward: TTCTGTGCTGTCCCAGTGAG 
Reverse: TGAAGAAAACCCCTTGTGCT 
Tnf-α Forward: CCACCACGCTCTTCTGTCTAC 
Reverse: AGGGTCTGGGCCATAGAACT 
MDM2 Forward: TGTGAAGGAGCACAGGAAAA 
 Reverse: TCCTTCAGATCACTCCCACC 
CXCL2 Forward: CGGTCAAAAAGTTTGCCTTG 
 Reverse: TCCAGGTCAGTTAGCCTTGC 
BAX Forward: GATCAGCTCGGGCACTTTAG 
 Reverse: TTGCTGATGGCAACTTCAAC 
BAD Forward: GTACGAACTGTGGCGACTCC 
 Reverse: GAGCAACATTCATCAGCAGG 
BAK1 Forward: AGACCTCCTCTGTGTCCTGG 
 Reverse: AAAATGGCATCTGGACAAGG 
BID Forward: GTGTAGCTCCAAGCACTGCC 
 Reverse: GCAAACCTTTGCCTTAGCC 
NOXA Forward: ACTTTGTCTCCAATCCTCCG 
 Reverse: GAAGTCGCAAAAGAGCAGGA 
PUMA Forward: CACCTAGTTGGGCTCCATTT 
 Reverse: ACCTCAACGCGCAGTACG 
Table 2 Oligonucleotide primer sequences used in the study 
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3.10 Protein isolation and western blotting 
3.10.1 Protein isolation 
Proteins from kidney tissue and cells from cell culture were extracted using RIPA buffer 
(Sigma, Germany) containing protease inhibitors (Roche, Germany). In brief, part of the 
kidney tissue stored at -80
0
C was homogenized using blade homogenizer for 30 seconds at 4 
in RIPA buffer (500µl) containing protease inhibitor. For cell culture experiments, after 
stimulations were over, cells were washed with PBS and then lysed in the RIPA buffer 
containing protease inhibitors. The lysates was then maintained at constant agitation for two 
hours at 4
0
C. The samples were then centrifuged for 20 min at 12000rpm at 4
0
C. Then the 
supernatant (proteins) was separated in new tube, pallet was discarded. Protein estimation was 
done using Barford´s assay. 
 
3.10.2 Western blotting 
After determination of protein concentrations, 50µg of the protein was mixed with 5x SDS 
loading buffer (100 mM Tris-HCl, 4% SDS, 20% glycerol, and 0.2% bromophenol blue) for 
Western blot analysis. Samples were heated at 95°C for 5 min. Proteins were separated by 
SDS PAGE and then transferred to a polyvinylidene difluoride (PVDF) membrane. 
Nonspecific binding to the membrane was blocked for 1hr at room temperature with 5% milk 
in Tris-buffered saline buffer (20 mM Tris-HCl, 150 mM NaCl, and 0.1% Tween 20). The 
membranes were then incubated overnight at 4°C with primary antibodies.  After washing, the 
membrane was incubated with respective secondary antibodies in Tris buffered saline buffer. 
The signals were visualized by an enhanced chemiluminescence system (Amersham, 
Buckinghamshire, UK). 
 
3.11 Magnetic cell sorting technique for isolation of renal cells 
In brief, kidneys were finely minced and digested for 30 min at 37 °C with 1 mg/ml 
collagenase D (Roche, Mannheim, Germany) and 0.1 mg/ml deoxyribonuclease type I 
(Sigma-Aldrich, Steinheim, Germany) in Hank's balanced salt solution. The digested tissues 
were washed and filtered through a 30-μm nylon mesh filter to remove debris and cell 
segments. Renal CD45+CD11c+ cells were isolated using microbead-conjugated antibodies 
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(Miltenyi Biotech, Bergisch-Gladbach, Germany). Magnetic bead separation was done 
according to the manufacturer's instructions. 
 
3.12 Electrophoretic mobility shift assay 
Electrophoretic mobility shift assay was performed using a LightShift Chemiluminescent 
EMSA Kit (Thermo Scientific, Rockford, IL). Following quantification of protein amounts by 
Bradford assay, 2 µg of nuclear extracts were analyzed for their binding activity to an IL-6- 
derived κB sequence–containing biotin end–labeled oligonucleotide probe. 50-biotin end-
labeled NF-κB oligonucleotides 50-AAATGTGG GATTTTCCCATGAGTCTC-30 and its 
reverse counterpart (Metabion) were annealed for the duplex probe. Binding reaction and 
electrophoresis on 6% native polyacrylomide gel were performed according to the 
manufacturer’s protocol and transferred on a nylon membrane. For oligonucleotide 
competitions, we added 20 ng of specific oligonucleotide competitor before adding the probe. 
The biotin end-labeled DNA is detected using the Streptavidin horse radish peroxidase 
conjugate and the chemiluminescent substrate. 
 
3.13 In-vitro methods 
3.13.1 Cell culture 
The mouse embryonic fibroblasts (MEFs) deficient either for p53 or p53/Mdm2 were kindly 
provided by Dr. G Lozano, University of Houston, TX and The murine macrophage cell line 
J774 were purchased from American Type Culture Collection, Rockville, MD, USA. To 
obtain CD133+CD24+ cells, total renal cells depleted for CD45 and CD31 were treated with a 
magnetic separation for CD133. The purified cell fractions consisted of >98% of 
CD133+CD24+ cells. Expression of WT1, nephrin, and CD133 was checked to evaluate the 
purity of podocyte cultures. Cells were plated in VRAD medium containing DMEM-F12 
(Sigma) supplemented with 10% FBS, vitamin D3 100 nM (Sigma), and all-trans retinoic acid 
(100 μM; Sigma). MEFs were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
(GIBCO/Invitrogen, Carlsbad, CA, USA) and J774 cells were maintained in RPMI medium 
(GIBCO/Invitrogen, Carlsbad, CA, USA). Both media were supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin. Cells were grown under standard conditions (in 
an incubator set at 37
0
C supplied with 5 % CO2/air). Trypsin was used for splitting the cells. 
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Cells were counted using Neubauers’ chamber and desired number of cells were used for 
experiments. 
 
3.13.2 Cell freezing and thawing 
At earlier passages large amounts of cells were grown under standard culture conditions and 
were frozen for future use. Cells to be frozen were detached from the culture plates and were 
spun down under sterile conditions for 3 min at 1000 RPM. The cell pellet was maintained on 
ice and carefully re-suspended in cold freezing medium (90 % respective culture medium and 
10 % DMSO) by pipetting the suspension repeatedly up and down. 1.5 ml aliquots were 
quickly dispensed into freezing vials (4
0
C). The cells were slowly frozen at –200C for 1 h and 
then at –800C overnight. The next day, all aliquots were transferred to liquid nitrogen. 
In order to thaw cells a frozen vial was removed from liquid nitrogen and put in a water bath 
at 37
0
C. The cells were then dispensed in 5 ml of warm complete growth medium and spun 
down at 1000 RPM for 5-7 min. Then the old medium was removed and the cells were re-
suspended in fresh medium and transferred to new culture plate. The medium was changed 
once more after 24 h. 
 
3.13.3 Stimulation experiments 
For cell stimulation experiments, the cells were seeded at a density of 5X10
5
 cells/well in six-
well plates in DMEM and grown overnight to confluence. Cells were treated with 5 µg/ml 
ultrapure LPS (InvivoGen, San Diego, CA) and incubated at 37
0
C, 5% CO2 for 0.5–18 h. 
Total cell protein was extracted for western blot analysis and supernatants were collected for 
IL-6 or TNF-α ELISA. Nuclear proteins were isolated by using high-salt extraction. 
 
3.13.4 In-vitro assessment of podocyte death 
To analyze cell death, cells were treated for 24 hours with adriamycin 0.2 µg/ml plus nutlin-
3a 10µM (Sigma) and harvested for propidium iodide (PI)/annexin V staining. Apoptotic cells 
were identified by double supravital staining with PI and recombinant APC-conjugated 
annexin V following the manufacturer's instructions (BD Biosciences, San Diego, CA). Data 
acquisition was performed using LSRII flow cytometer (BD Biosciences) and data were 
analyzed with FlowJo software (Tree Star, Inc. Ashland, OR). 
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3.14 Statistical analysis 
Data are presented as mean ±SEM. For multiple comparison of groups one way ANOVA was 
used followed by post-hoc Bonferroni`s test, using SigmaStat (Jandel Scientific, Erkarath, 
Germany). Paired Student`s t-test was used for the comparison of single groups. A value of p 
< 0.05 was considered to indicate statistical significance. 
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4. Results 
4.1 Part I MDM2 inhibition in ischemia reperfusion induced acute kidney injury 
 
4.1.1 MDM2 expression in the healthy and postischemic kidney 
To start out, MDM2 mRNA expression screen in solid organs of healthy adult C57BL/6 mice 
was performed. The highest MDM2 mRNA expression levels were found in muscle and heart, 
whereas the renal MDM2 mRNA levels were more in the range of lung, colon, urinary 
bladder, and brain (Figure 11A). Immunostaining localized MDM2 to the cytoplasm of 
epithelial cells in proximal and distal tubuli, and probably to podocytes inside glomeruli 
(Figure 11B). Next, the MDM2 expression in postischemic and sham kidneys 1 and 5 days 
after renal pedicle clamping was determined by western blot analysis. MDM2 protein levels 
were reduced in both kidneys, postischemic and sham-operated, at day 1 but MDM2 levels 
recovered in sham kidneys at day 5 (Figure 11C). Furthermore, p53 protein expression was 
strongly induced in postischemic kidneys at 24h and remains elevated at day 5 after ischemia–
reperfusion. Together, inside the kidney MDM2 is mainly expressed by (tubular) epithelial 
cells. 
 
4.1.2 MDM2 blockade prevents early postischemic AKI 
To address a putative functional contribution of MDM2 to AKI, MDM2 function was blocked 
using nutlin-3a, a small-molecule MDM2 antagonist that inhibits MDM2-mediated 
degradation of p53 leading to cell cycle arrest and apoptosis in various cancer cells
142
. The 
hypothesis was that nutlin-3a treatment would elicit a similar effect in AKI, i.e., foster p53-
mediated tubular cell apoptosis, a process that should aggravate the early phase of 
postischemic injury. However, MDM2 blockade with nutlin-3a rather significantly reduced 
serum creatinine levels at 24 h after bilateral renal artery clamping as compared with vehicle-
treated C57BL/6 mice (Figure 12A). This protective effect was associated with less tubular 
injury in postischemic kidneys at 24h also after unilateral renal artery clamping (Figures 12B 
and C), and immunostaining for either brush border lectin or Tamm–Horsfall protein revealed 
that this protective effect applied to proximal and distal tubules, respectively (Figure 13). In 
AKI, loss of intact tubules involves both tubular cell necrosis and apoptosis
148
. Interestingly,  
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Figure 11 Renal murine double minute-2 (MDM2) expression A. Total mRNA was isolated from different 
organs of adult C57BL/6 mice and MDM2 mRNA expression levels were quantified by reverse transcription-
polymerase chain reaction. Data are expressed as ratio of MDM2 mRNA to the respective 18s rRNA level in 
mean±s.e.m. from samples of five mice. B.  MDM2 immunostaining (red) was performed on paraffin-embedded 
kidney samples of adult C57BL/6 mice. Lotus tetragonolobus lectin stains the brush border of proximal tubuli in 
green. 4,6-Diamidino-2-phenylindole stains nuclei in blue. Note the cytoplasmic staining pattern of MDM2 in 
proximal and distal tubuli in cortex (upper left) and medulla (lower right), which is absent in negative control 
stains (upper right). Few resident glomerular cells express MDM2 (lower left). Original magnification × 400. C. 
The expression of MDM2 and p53 in ischemic–reperfusion (IR) and contralateral (Co) kidneys at 1 day and 5 
days was determined by western blot analysis. β-Actin staining is shown as loading control. The graph on the 
right shows a quantitative analysis of several blots. *P<0.05, **P<0.01 vs. baseline. 
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Figure 12 MDM2 blockade and postischemic acute kidney injury A. Serum creatinine levels were 
determined 24 h after bilateral renal artery clamping. Data are mean±s.e.m. from six mice in each group. B. 
Tubular injury was quantified on periodic acid–Schiff (PAS)-stained renal section at day 1 and 5 after unilateral 
renal artery clamping as described in methods. IR, ischemia–reperfusion kidney; Co, contralateral kidney. 
**P<0.01 nutlin-3a- vs. vehicle-treated mice. C. Representative images from PAS stains of all groups are shown 
at original magnification of × 100.  
 
MDM2 blockade significantly reduced the numbers of terminal deoxytransferase uridine 
triphosphate nick end labeling (TUNEL)-positive tubular cells (Figure 14). These results were  
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Figure 13 Postischemic injury of proximal and distal tubuli Lotus tetragonolobus lectin staining identified 
proximal tubuli (A) and Tamm–Horsfall protein staining identified distal tubuli (B) in postischemic kidneys. The 
quantitative assessment of tubuli with intact staining patterns is shown for each staining. Data are mean±s.e.m. 
from six mice in each group. *P<0.05, **P<0.01 nutlin-3a- vs. vehicle-treated mice. All images are shown at 
original magnification of × 100. 
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Figure 14 Renal cell apoptosis after renal ischemia–reperfusion A. TUNEL staining (green) identified 
apoptotic renal cells in postischemic kidneys. DAPI staining of cell nuclei is shown in blue. Original 
magnification of upper panel × 100, lower panel × 400. B.  The quantitative assessment of TUNEL-positive cells 
per high-power field (h.p.f.) is shown as mean±s.e.m. from six mice in each group. *P<0.05, **P<0.01 nutlin-3a- 
vs. vehicle-treated mice. Co, contralateral kidney; DAPI, 4,6-diamidino-2-phenylindole; IR, ischemia–
reperfusion kidney; TUNEL, terminal deoxytransferase uridine triphosphate nick end labeling. 
 
 
 
Figure 15 MDM2 and p53 protein expression in postischemic kidneys Total proteins were extracted from 
kidneys of vehicle- and nutlin-3a-treated C57BL/6 mice at day 1 and day 5 after renal artery clamping as 
indicated. β-Actin expression is shown as a loading control. 
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unexpected since the anticipation was that MDM2 blockade would enhance tubular cell 
apoptosis by promoting p53 activation in AKI
14-16
. 
To verify the potential of nutlin-3a to activate p53 in vivo, western blots was performed from 
the kidney protein isolates for total p53 and for phosphorylated, i.e. activated, p53. As 
expected, nutlin-3a treatment slightly increased the protein levels of p53 at 24h after renal 
artery clamping (Figure 15), presumably by inhibiting MDM2-mediated p53 degradation. 
Furthermore, nutlin-3a treatment slightly increased the protein levels of activated p53 and also 
the expression of p53-dependent apoptotic genes (Figures 15 and 16A), whereas the levels of 
MDM2 and phosphorylated MDM2 remained unaffected by nutlin-3a treatment (Figure 15).  
Together, MDM2 blockade with nutlin-3a stabilizes and activates p53 in the postischemic 
kidney. As p53 activation is known to contribute to postischemic tubular cell apoptosis and 
AKI, it has been assumed that the protective effect of MDM2 blockade on early AKI is 
mediated via another, p53-independent, pathomechanism of AKI. 
 
4.1.3 MDM2 promotes postischemic renal inflammation in a p53-independent manner 
To verify p53-independent effects of MDM2 blockade in early AKI, the same set of 
experiments were performed in p53-deficient mice (Figure 17). A comparison of AKI 24h 
after renal artery clamping revealed no difference in the renal phenotype of wild-type or p53-
deficient mice with nutlin-3a treatment as evidenced by the tubular injury score or the 
percentages of lectin or Tamm–Horsfall protein–positive proximal and distal tubuli, 
respectively (Figure 17). Moreover, the numbers of infiltrating neutrophils, F4/80 
macrophages, or CD3 T cells were not affected by the p53 genotype. 
In analyzing other disease pathomechanism of AKI that could involve MDM2 in a p53-
independent manner, postischemic renal inflammation was evaluated. Oxidative stress and 
cell necrosis are important stimuli of sterile inflammation, and inflammatory cytokines and 
infiltrating immune cells contribute to postischemic tissue injury
20,149
. Ischemia–reperfusion 
strongly induced intrarenal mRNA expression of several pro-inflammatory mediators such as 
CXCL2, CCL2, interleukin (IL)-6, and the proapoptotic cytokine tumor necrosis factor 
(TNF)-α within 24h, an effect that was suppressed by MDM2 blockade (Figure 18A). 
Whereas IL-6 expression derived from different types of resident immune cells and renal 
parenchymal cells, MDM2 blockade suppressed the induction of TNF-α, CXCL2, and CCL2 
mainly in intrarenal CD11c-positive dendritic cells (Figure 18B).  
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Figure 16 Nutlin-3a induces proapoptotic p53 target genes in postischemic kidneys Total RNA was 
extracted from postischemic kidneys after renal artery clamping (A) at day 1 (B) at day 5. The mRNA expression 
levels were determined for the indicated genes by real-time polymerase chain reaction. Data are expressed as 
mean of the ratio vs. the respective 18s rRNA level±s.e.m. 
*
P<0.05 vs. vehicle-treated mice. 
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Figure 17 MDM2 blockade and acute kidney injury in wild-type (WT) and p53-deficient mice Left column: 
Tubular injury was quantified on periodic acid–Schiff (PAS)-stained (upper graph), Lotus tetragonolobus lectin–
stained (middle graph), and Tamm–Horsfall protein–stained sections (lower graph) of postischemic kidneys at 
day 1 and 5 after unilateral renal artery clamping as described in methods. p53 KO=p53-deficient mice. Right 
column: The same sections were stained for neutrophils (upper graph), CD3+ T cells (middle graph), and F4/80+ 
macrophages (lower graph). Neutrophils and T cells were quantified per high-power field (h.p.f.) and expressed 
as mean±s.e.m. of 15 h.p.f. Macrophages were quantified by assessing the percentage of staining-positive area 
via digital morphometry and are expressed as mean±s.e.m. of 15 h.p.f. 
*
P<0.05 vs. wild-type vehicle treated 
mice, 
+
P<0.05 vs. wild-type nutlin-3a treated mice. 
 
Accordingly, the numbers of infiltrating neutrophils (but not of F4/80+ macrophages or CD3+ 
T cells) were significantly reduced after 24h in postischemic kidneys of nutlin-3a-treated 
wild-type mice (Figure 19). There were no significant changes in MDM2 mRNA expressions 
in renal cells. The given knowledge about MDM2 inhibition by nutlin-3a rather suggests 
proapoptotic–antiproliferative effects that rule out the assumption of tissue protection during 
AKI. Together, MDM2 blockade ameliorates postischemic AKI by suppressing the sterile 
inflammatory response inside the kidney in a p53-independent manner. 
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Figure 18 MDM2 blockade and inflammatory mediator expression in postischemic kidneys A. Total 
mRNA was prepared from vehicle- (black bars) or nutlin-3a-treated (white bars) C57BL/6 mice at day 1 or 5 
after unilateral renal artery clamping as indicated. 
*
P<0.05 vs. vehicle-treated mice. B. CD45+ leukocytes and 
CD45− renal parenchymal cells were separated from postischemic kidneys of both treatment groups 24 h after 
renal artery clamping by magnetic bead isolation as described in Materials and Methods. The CD45+ cell 
population was further separated into CD11c+ ‘dendritic cells’ and CD11c− other leukocytes. The mRNA 
expression levels were determined for the indicated cytokines and chemokines by real-time polymerase chain 
reaction and are expressed as mean of the ratio vs. the respective 18s rRNA level±s.e.m. P-levels for the 
comparison of nutlin-3 vs. vehicle treatment are as indicated. Co, contralateral ‘sham’ kidney; IL, interleukin; 
IR, clamped kidney; TNF, tumor necrosis factor. 
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Figure 19 MDM2 blockade and leukocyte infiltrates in postischemic kidneys Renal sections from 
postischemic (IR) and contralateral kidneys (Co) were stained for different leukocyte markers as described in 
methods. Neutrophils and CD3+ T cells were counted per h.p.f. F4/80 positive macrophages were quantified by 
digital morphometry and data are expressed as percentage of h.p.f. Data are means ± SEM of 15 h.p.f. from at 
least 6 mice in each group. *p < 0.05 versus vehicle-treated mice of the respective time point. 
 
 
 
Figure 20 Scratch Assay A scratch of similar size was made into monolayers of p53-deficient and p53/Mdm2-
double deficient MEFs. The images illustrate that the MDM2 genotype did not affect the time that was necessary 
to close the gap. 
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4.1.4 MDM2 is required for NF-κB target gene transcription 
How MDM2 can affect the expression of pro-inflammatory cytokines? To answer this 
question, p53-deficient and p53/Mdm2 double-deficient mouse embryonic fibroblasts (MEFs) 
were used as a reliable and validated experimental system to identify p53-independent effects 
of MDM2
129
. Because postischemic renal inflammation is largely mediated via MyD88 and 
TLR4
26
, the TLR4/MyD88 agonist lipopolysaccharide (LPS) was used to activate the cells 
and cytokine production was measured after 18 h by enzyme-linked immunosorbent assay. 
Lack of MDM2 completely prevented LPS-induced TNF-α production and strongly reduced 
IL-6 release by p53-deficient MEFs (Figure 21A). Theoretically, the difference in cytokine 
production could be secondary to different cell survival or cell growth of the two cell lines. 
This was ruled out by comparing cell viability and scratch-induced wound healing of cell 
monolayers. Both cell lines grew at the same rate and healed scratch wounds within the same 
time interval (Figure 20). Thus, MDM2 is required for TLR-induced cytokine production, an 
effect that obviously does not require p53.  
To further explore the molecular mechanism by which MDM2 promotes cytokine induction, 
the signaling events occurring after TLR4 activation were investigated by western blot 
analysis, namely the expression levels of nuclear factor (NF)-κB p65, IκBα, p38 mitogen-
activated protein kinase (MAPK), p44/42 MAPK, and their phosphorylated forms. To verify 
the results, a similar set of experiments was performed in J774 macrophages treated with 
MDM2 inhibitor or vehicle. There were no significant differences found between the two 
genotypes of MEF, or between nutlin-3a-treated and untreated macrophages, that could 
explain the lack of LPS-induced cytokine induction in p53/Mdm2 double-deficient MEFs 
(Figure 21B, Figure 22). Thus, MDM2 should modulate TLR-induced cytokine expression 
beyond the level of NF-κB signaling.  
Therefore, whether MDM2 modulates the capacity of NF-κB to interact with the promoter 
region of its target genes, namely the binding activity of NF-κB to the κB site of the IL-6 
promoter was determined. This was tested by gel-shift analysis of nuclear extracts that were 
prepared 1h after LPS stimulation in both types of cells. Lack of MDM2 significantly 
impaired LPS-induced NF-κB binding activity to the IL-6 promoter (Figure 21C). NF-κB 
activation by LPS in the p53-deficient and p53/Mdm2-double deficient MEFs was also 
examined by using NF-κB-luciferase reporter assay and showed lower level of activation of 
NF-κB in the cells lacking MDM2 (Figure 22).  
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Figure 21 In-vitro studies with p53- and p53/Mdm2-deficient mouse embryonic fibroblasts A. Mouse 
embryonic fibroblasts (MEF) either deficient for p53 or p53/Mdm2 were stimulated with 5 μg/ml LPS, and IL-6 
and TNF-α levels in the supernatants were measured after 18 h. B. Effect of LPS stimulation of TLR4 on 
different signaling pathways in both cell lines after 0.5, 1, and 3 h. The graph shows western blots for the 
respective TLR signaling proteins. β-Actin is shown as loading control. C. LPS-induced NF-κB binding to IL-6 
promoter region DNA was studied in both cell lines by electrophoretic mobility shift assay. Binding site–specific 
competitor DNA and nonspecific noncompeting DNA were used to document NF-κB's interaction with the 
sequence-specific binding site. The data are representative of three independent experiments. IL, interleukin; 
LPS, lipopolysaccharide; MDM2, murine double minute-2; ND, not determined; NF-κB, nuclear factor-κB; 
TLR, Toll-like receptor. 
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Figure 22 Effect of LPS stimulation on p53-/- and MDM2/p53-/- MEFs as well as on J774 macrophages 
treated with or without nutlin-3a and NF-κB luciferase activity A,B. NF-kB signaling pathway in p53-/- and 
MDM2/p53-/- MEFs after 0,5, 1, and 3 hours of LPS stimulation in cytoplasmic and nuclear protein extracts. 
C,D. NF-kB signaling pathway in J774 cells pretreated with nutlin-3a or DMSO after 0.5, 1, and 3 hours of LPS 
stimulation in cytoplasmic and nuclear protein extracts. Data were western blots for the respective NF-kB 
signaling proteins. α-tubulin and histone 3 are shown as loading controls for cytoplasmic and nuclear extracts 
respectively. Data are representative of three independent experiments. E. The p53-deficient and p53/Mdm2-
double deficient cells were cotransfected with pNF-κB-luc and Renilla reporter vectors. 24 hours 
posttransfection the cells were treated with 1µg/ml LPS or vehicle for 5 hours and processed using the dual 
luciferase reporter system (Promega). Activities of firefly and Renilla luciferases were measured by 
luminometer. Firefly luciferase activity was divided by Renilla luciferase activity to correct for differences in 
transfection efficiencies. Experiments were done in triplicates. 
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Figure 23 MDM2 blockade and postischemic AKI Serum BUN levels were determined at day 1 and day 5 
after bilateral renal artery clamping for 30min. Data are means ± SEM from 5 mice in each group 
 
Together, MDM2 has a p53-independent function in facilitating the binding of NF-κB to the 
promoter of its target genes, an effect that promotes TLR-induced expression of pro-
inflammatory cytokines or chemokines and that appears to contribute to postischemic renal 
inflammation and AKI. 
 
4.1.5 MDM2 drives tubular regeneration 
Postischemic renal inflammation and tubular damage is transient and followed by tubular 
regeneration, which is similar to epithelial regeneration in other organs including dermal 
wound healing
150
. Tubular regeneration involves and requires the proliferation of surviving 
tubular cells or tubular progenitors in each single nephron to restore the nephron's 
physiological functions. To address whether MDM2 does also modulate this phase of AKI, 
both renal arteries were clamped for 30 min and serum blood urea nitrogen was monitored, 
with or without nutlin-3a treatment. Nutlin-3a protected renal function at the early phase but 
aggravated it at later phase of tubular regeneration (Figure 23). Furthermore, the postischemic 
and contralateral kidneys were studied at day 5 after unilateral renal artery clamping for 
45 min. Although MDM2 blockade had significantly reduced AKI at day 1 after ischemia–
reperfusion, the tubular injury was rather aggravated at day 5 as compared with vehicle-
treated wild-type mice (Figures 12B, 12C and 14). MDM2 blockade increased the numbers of 
TUNEL-positive cells in postischemic kidneys at day 5 (Figure 14B), indicating that MDM2 
blockade enhanced tubular cell apoptosis in the regeneration phase of AKI. In fact, MDM2 
blockade induced the intrarenal mRNA expression levels of several proapoptotic p53 target 
genes such as BAX, BAD, BAK, BID, and NOXA at day 5 after renal artery clamping 
(Figure 16B).  
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This effect was consistent with the initial hypothesis and also MDM2 blockade increased the 
intrarenal protein levels of p53 and activated p53 at day 5 (Figure 15), therefore the putative 
dependency of the proapoptotic effect of MDM2 blockade on p53 was questioned. Consistent 
with this concept, p53-deficient mice were found to be entirely protected from nutlin-3a-
mediated aggravation of tubular injury and to have less renal immune cell infiltrates at day 5 
as compared with wild-type mice (Figure 17). Furthermore, lack of MDM2 had no effect on 
the healing of scratched monolayers of p53-deficient MEFs (Figure 20). 
 
In summary, MDM2 blockade with nutlin-3a suppresses the early postischemic renal 
inflammation by inhibiting the p53-independent effects of MDM2 on NF-κB signaling. In 
contrast, nutlin-3a aggravates AKI in the healing phase by inhibiting the suppressive effect of 
MDM2 on p53-mediated cell cycle arrest and apoptosis.  
The conclusion is MDM2 has a dual role in postischemic AKI as it mediates both renal 
inflammation and epithelial regeneration. 
 
4.2 Part II MDM2 inhibition in adriamycin induced focal segmental glomerulosclerosis 
4.2.1 MDM2 is expressed in glomerular epithelial cells in healthy & AN kidney 
Confocal microscopy of Balb/c mouse kidneys localized MDM2 mostly to the perinuclear 
cytoplasm of podocytes as indicated by costaining with nephrin (Figure 24A). Podocyte foot 
processes that cover the circumference of the glomerular capillaries were MDM2 negative 
which excludes any direct contribution of MDM2 to the slit membrane or to the distal 
cytoskeleton of secondary foot processes (Figure 24A). Claudin-1 positive PECs also 
displayed a positive cytoplasmatic staining signal which, however, was less prominent (Figure 
24B). Proximal and distal tubules were also strongly positive for MDM2 (Figure 24C). 
MDM2 staining patterns did not change throughout the course of AN (Figures 25 and 26). 
Western blotting confirmed that renal MDM2 expression was not regulated throughout AN, 
while p53 was induced with time (Figure 24D). 
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Figure 24 MDM2 expression in Balb/c mice A-C: MDM2 immunostaining (red) was assessed by confocal 
microscopy. A: In glomeruli the expression mostly co-localized with nephrin (green) which mark podocytes. B: 
Weaker MDM2 positivity is present also in parietal epithelial cells co-stained with claudin-1 (green) as indicated 
by white arrows. Original magnification 400x. C: In the tubulointerstitial compartment MDM2 staining localized 
to lectin positive proximal tubules as well as to lectin negative distal tubules (latter marked by white arrows). 
Original magnification 200x. D: The expression of p53 and MDM2 during the course of AN was determined by 
western blot. β-actin is shown as loading control. 
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Figure 25 MDM2 expression in glomerulus throughout the course of AN MDM2 immunostaining (red) was 
assessed by confocal microscopy. In glomeruli the expression mostly colocalized with nephrin (green) which 
mark podocytes.  Original magnification 400x. 
 
Figure 26 MDM2 expression in tubular compartment throughout the course of AN In the tubulointerstitial 
compartment MDM2 staining (red) localized to lectin positive proximal tubules (green) as well as to lectin 
negative distal tubules. Original magnification 200x. 
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Figure 27 MDM2 blockade and glomerular disease in early AN A: Representative images of glomeruli from 
PAS stains of all groups are shown at a magnification of 200x. B: Glomerular lesions were quantified on PAS-
stained renal sections as described in the text. C. Proteinuria, plasma creatinine and plasma BUN were 
determined at week 1 and week 2. Data are means ±SEM. * p<0.05 nutlin-3a- versus vehicle-treated mice at 
week 2. 
 
Together, MDM2 is predominantly expressed in the monolayer of renal epithelial cells along 
the nephron, including podocytes, PECs, and tubular epithelia but its expression is not 
regulated during the progression of AN. 
 
4.2.2 MDM2 blockade prevents glomerular pathology and renal dysfunction 
The small molecule MDM2 antagonist nutlin-3a was used to determine the functional role of 
MDM2 during early and advanced AN. The first injection of adriamycin induced proteinuria  
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Figure 28 Semi-quantitative assessments of glomerular lesions Using these criteria Balb/c mice with AN 
displayed a progressive decrease in the numbers of glomeruli with no lesions in favor of progressively increasing 
numbers of glomeruli with global lesions. Treatment with nutlin-3a from week 2-4 had no significant effect on 
these measures. Data are mean±SEM for each time point. 
 
and segmental lesions with tuft adhesions to Bowman`s capsule which was associated with a 
rise in serum creatinine and BUN levels as markers of an impaired excretory renal function 
(Figures 27A-27C). Global glomerular lesions developed only after week 1 (Figure 27B and 
28). At the end of week 1 one group of mice with AN received nutlin-3a and another group 
received vehicle. At the end of week 2 vehicle-treated mice had diffuse lesions (means 
affecting almost all glomeruli), of which around 50% displayed global lesions (means more 
than half of the glomerular tuft injured) (Figure 27B). This was associated with a further 
increase of proteinuria and BUN levels compared to week 1 (Figure 27C). Nutlin-3a treatment 
significantly reduced this progression of glomerular injury in terms of all of these structural 
parameters as well as BUN levels (Figures 27A-27C).  
Thus, MDM2 expression in glomerular epithelial cells contributes to the progression of 
glomerular pathology, proteinuria, and renal failure in early AN. 
 
4.2.3 MDM2 blockade prevents glomerular inflammation and podocyte loss 
Human and experimental FSGS is driven by the loss of podocytes
61,110
 hence, we quantified 
podocytes by co-staining for WT-1 and nephrin (Figure 29A). Healthy mice had an average of 
15 WT-1/nephrin+ cells per glomerulus which decreased to around 8 and 6 at week 1 and 2 
after injection, respectively (Figure 29B). Nutlin-3a treatment starting from the end of week 1 
significantly increased the number of podocytes as compared to vehicle-treated mice at the 
end of week 2 (Figures 29A and 29B), a result consistent with nutlin-3a`s effect on 
proteinuria (Figure 27C). 
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Figure 29 MDM2 blockade reduces podocytes injury and glomerular inflammation A: WT-1/nephrin co-
staining was used to quantify differentiated podocytes in kidneys of vehicle- and nutlin-3a- treated kidneys. 
Original magnification 400x. B: Numbers of nephrin/WT-1 double-positive cells were quantified in both groups. 
B: Total mRNA was prepared from vehicle- and nutlin-3a- treated kidneys. The mRNA expression levels were 
determined for the indicated cytokines and chemokines by real-time PCR and expressed as mean of the ratio 
versus the respective 18s rRNA level. C: Renal sections from vehicle- and nutlin-3a- treated kidneys were 
stained for different leukocyte markers as described in methods. CD3+ T cells and Mac-2+ cells were counted 
per glomerulus. All data are means ± SEM. * p< 0.05, ** p<0.01 versus vehicle group. 
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Total kidney mRNA expression of IL-6, TNF-α, iNOS, CCL2, and IP-10/CXCL10 increased 
from week 1 to week 2 of AN (Figure 29B). Nutlin-3a treatment from the end of week 1 
entirely prevented this induction of all of these pro-inflammatory mediators (Figure 29B). 
CCL2 and IP-10/CXCL10 are known to mediate macrophage and T cell recruitment into the 
kidney
151
, therefore, we assessed the numbers of glomerular macrophages and T cells by  
immunostaining. Nutlin-3a significantly reduced the numbers of intraglomerular Mac2+ 
macrophages and CD3+ T cells as compared to vehicle-treated mice with AN (Figure 29C) 
suggesting that MDM2 blockade can potently block glomerular inflammation. 
Thus, MDM2 blockade prevents glomerular inflammation and podocyte loss in early AN. 
 
4.2.4 Nutlin-3a prevents adriamycin-induced podocyte death by mitotic catastrophe 
To see, whether MDM2 blockade with nutlin-3a had direct or indirect effects on podocyte 
death in AN, the effects of MDM2 blockade with nutlin-3a on adriamycin-induced podocyte 
death were studied in-vitro. CD133+/CD24+ renal progenitor cells were differentiated into 
mature podocytes before exposing them to adriamycin in the presence of either nutlin-3a or 
vehicle. Cell death was analyzed by propidium iodine (PI) and annexin V staining per flow 
cytometry. Adriamycin increased the numbers of PI positive podocytes, an effect that was 
significantly reduced by nutlin-3a (Figure 30A and 30B). Immunostaining of the mitotic 
spindle with tubulin and for cell cycle metaphase with histone-3 phosphorylated at serine 10 
confirmed that adriamycin induced aberrant mitotic spindles and abnormal nuclear shapes 
(Figure 30C). Together, MDM2 enhances adriamycin-induced podocyte death by pushing 
podocytes to complete mitosis which can destroy podocytes through mitotic catastrophe. This 
process can be prevented by nutlin-3a. (The presented in-vitro experiments were carried out 
in collaboration with University of Florence, Italy.) 
 
4.2.5 Effect of MDM2 blockade on p21 expression and podocyte mitosis in AN 
To assess this phenomenon also in-vivo, we performed immunostaining for histone H3 
phosphorylated at serine 10 (H3-P) and the podocyte marker podocin. H3-P marks the 
prophase of nuclear division and, therefore, displays cells that are about to complete mitosis. 
H3-P/podocin positivity was absent in healthy mouse kidneys (Figure 30D). AN in Balb/c 
mice was associated with the presence of some H3-P positive podocytes and their number was  
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Figure 30 Nutlin-3a affects adriamycin-induced podocyte death in-vitro Podocytes were generated, cultured 
in VRADD medium, and exposed to adriamycin (ADR) as described in methods. A and B: Flow cytometry 
analysis of cultured podocytes for propidium iodine (PI) and annexin V 24 hours after stimulation. Data 
represent means ±SD of 4 identical experiments (A) and representative dot blots are shown (B). * p<0.05 versus 
the ADR (+vehicle) group. C: Immunostaining of podocytes for histone 3 phosphorylated at the serine 10 residue 
(H3-Ser10) serves as a marker for cells within the metaphase in green. Tubulin staining marks the mitotic 
spindle in red. To-pro-3 marks the chromatin inside the nucleus in blue. Note that immature podocytes 
proliferate by forming normal mitotic spindles and appropriate chromosomal alignment in the metaphase plate in 
between the spindles (control). Mature podocytes do not proliferate any more in culture but adriamycin induced 
mitotic events with abnormal assembly of the mitotic spindles with abnormal nuclear as a an indicator of 
aberrant chromosomal division and mitotic catastrophe leading to cell death. Original magnification of x1000. D: 
Immunostaining for podocin (red), H3-Ser10 (yellow) double positive cells in renal sections of Balb/c mice with 
AN. To-pro-3 marks the chromatin inside the nucleus in blue at an original magnification of x400). Data in the 
graph are expressed as mean±SEM. ** p<0.01 nutlin-3a- versus vehicle-treated mice at week 2. E: Western blot 
for p21 on mouse kidney isolates harvested from nutlin-3a and vehicle treated Balb/c mice at 2 weeks. Note that 
p21 expression is stronger upon nutlin-3a treatment. Quantification of p21 bands versus ß-actin is shown on the 
right. 
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significantly reduced in nutlin-3a-treated mice (Figure 30D). By contrast, TUNEL positive 
podocytes could not be detected (not shown). This finding correlated with an increase of 
intrarenal p21 expression (Figure 30E), a cyclin-dependent kinase inhibitor mediating the 
p53-dependent G1 phase cell cycle arrest. Thus, MDM2 blockade with nutiln-3a prevents 
podocyte loss in AN by reducing podocyte mitosis, a process that is associated with podocyte 
depletion, proteinuria, and FSGS. 
 
4.2.6 Delayed MDM2 blockade prevents the progression of AN 
Progression of sclerosis of a single glomerulus involves the loss of the associated tubules so 
that eventually the entire nephron degenerates, a process involving its removal by phagocytes 
and replacement by fibrous tissue
152
. Therefore, progressive glomerulosclerosis is associated 
with tubular atrophy as well as a progressive inflammatory response and fibrosis of the 
tubulointerstitial compartment
152,153
. The same applies for the later phase of adriamycin-
induced glomerulosclerosis. In order to study how MDM2 blockade affects this phase of AN, 
mice with AN at 2 weeks after the first injection of adriamycin were randomized for treatment 
with either nutlin-3a or vehicle for 14 days and renal function and tubulointerstitial pathology 
were assessed at the end of week 4. MDM2 blockade significantly reduced plasma creatinine 
levels and BUN as compared to vehicle-treated mice; this was associated with significantly 
less tubular atrophy (Figures 31A and 31B). By contrast, proteinuria and glomerular damage 
were not all affected by nutlin-3a. This suggests that in advanced AN, MDM2 blockade 
prevents renal dysfunction mainly by preventing progression of tubular atrophy. 
 
4.2.7 Delayed MDM2 blockade prevents AN-related tubulointerstitial inflammation 
MDM2 blockade in early AN suppressed inflammation but not a proliferative epithelial 
response inside the glomerulus as evaluated by the numbers of Ki-67+ glomerular cells 
(Figure 32A). MDM2 blockade obviously also did not suppress tubular cell proliferation in 
the later phase as evaluated by the numbers of Ki-67+ tubular cells (Figure 32B). Therefore, it 
was speculated that MDM2 blockade improved the tubulointerstitial damage of advanced AN 
rather by suppressing renal inflammation. In fact, real time PCR of total kidney mRNA 
revealed that nutlin-3a treatment from week 2 to 4 significantly reduced the intrarenal mRNA 
expression of TNF-α, iNOS, CCL2, and IP-10/CXCL10 (Figure 33A). This was associated  
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Figure 31 MDM2 blockade and progression of AN A: Representative images of kidneys at week 2 from PAS 
stains of vehicle- and nutlin-3a- treated groups are shown at a magnification of 100x. Inserts shows 
representative glomeruli from the same kidneys at a magnification of 400x. B: Plasma creatinine, plasma BUN, 
and proteinuria were determined at several time points as indicated. Semi-quantitative analysis of tubular atrophy 
was compared between vehicle- and nutlin-3a- treated groups as described in methods. Data are means ±SEM. * 
p<0.05 nutlin-3a- versus vehicle-treated mice at week 4. 
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Figure 32 MDM2 blockade and proliferation of kidney cells Renal sections from vehicle- and nutlin-3a- 
treated kidneys were stained for different Ki-67, a cell proliferation marker as described in methods. A: 
Quantitative assessment of number of proliferating glomerular cells from vehicle- and nutlin-3a- treated kidneys 
at respective time points, from week 1-2 (left graph) and from week 2-4 (right graph). B: Quantitative 
assessment of number of proliferating tubular cells from vehicle- and nutlin-3a- treated kidneys at respective 
time points, from week 1-2 (left graph) and from week 2-4 (right graph). Data are means ± SEM. 
 
with a significant reduction of interstitial F4/80+ macrophages and CD3+ T cells (Figure 
33B).  
Thus, delayed MDM2 blockade prevents CKD progression and prevents tubular atrophy by 
suppressing intrarenal cytokine and chemokine expression and recruitment of leukocytes. 
 
4.2.8 Delayed MDM2 blockade prevents AN-related interstitial fibrosis  
The progression to ESRD involves renal tissue remodeling by replacement of lost renal 
parenchyma by extracellular matrix
154
. As such, renal fibrosis is another histopathological  
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Figure 33 MDM2 blockade and tubulointerstitial inflammation in AN A: Total mRNA was prepared from 
vehicle- and nutlin-3a- treated kidneys. The mRNA expression levels were determined for the indicated 
cytokines and chemokines by real-time PCR and expressed as mean of the ratio versus the respective 18s rRNA 
level ± SEM. p levels for the comparison of nutlin-3a- versus vehicle treatment are as indicated. B: Renal 
sections from vehicle- and nutlin-3a- treated kidneys at week 4 were stained for different leukocyte markers as 
described in methods. F4/80 positive macrophages were quantified by digital morphometry and data are 
expressed as percentage of hpf. CD3+ T cells were counted per hpf. Data are means ± SEM of 25 hpf per kidney 
per group. * p<0.05 nutlin-3a versus vehicle-treated mice at week 4. 
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Figure 34 MDM2 blockade and interstitial fibrosis A: Representative images of kidneys at week 4 from α-
SMA stains of vehicle- and nutlin-3a- treated groups are shown at a magnification of 200x. B: α-SMA positive 
area was quantified by digital morphometry and data are expressed as percentage of hpf. C: Total mRNA was 
prepared from vehicle- and nutlin-3a- treated kidneys. The target mRNA expression levels were determined by 
real-time PCR and expressed as mean of the ratio versus the respective 18s rRNA level ± SEM. Data are means 
± SEM. * p<0.05 nutlin-3a- versus vehicle-treated mice at week 4. 
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marker of CKD and a predictor of ESRD
153
. MDM2 blockade from week 2 to week 4 with 
nutlin-3a improved intrarenal alpha-smooth muscle actin expression (Figure 34A and 34B) a 
marker of myofibroblasts that account for most of the extracellular matrix deposited in renal 
fibrosis
154
. This process of transition is triggered by TGF-β, which was also found to be 
significantly reduced upon nutlin-3a treatment (Figure 34C). Also mRNA expression of 
alpha-smooth muscle actin and collagen-1alpha1 were significantly reduced (Figure 34C).  
 
These data demonstrate that even delayed MDM2 blockade has the potential to prevent the 
progression of glomerulosclerosis to CKD due to subsequent tubulointerstitial inflammation 
and fibrosis. 
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5. Discussion 
MDM2 negatively regulates p53 activity, mainly by inducing the ubiquitin-mediated 
degradation of p53, thereby suppressing coordinated cell cycle arrest or apoptosis and 
promoting cell survival and growth
119
. Therefore, it was hypothesized that the suppressive 
effect of MDM2 on p53 activity would prevent cell cycle arrest and cell death upon oxidative 
and/or genotoxic stress and similarly, that MDM2 blockade would aggravate postischemic 
AKI as well as AN. The finding of the present study that MDM2-mediated suppression of p53 
is required for tubular regeneration in the healing phase of AKI is partially consistent with this 
concept. However, as an unexpected finding, MDM2 also had a p53-independent pro-
inflammatory effect in the early injury phase of AKI. This is also true in chronic renal failure, 
since MDM2 blockade reduced the glomerular as well as tubulointerstitial inflammation in 
AN. This additional pro-inflammatory function of MDM2 was previously unknown. 
 
The findings of the present study have multiple implications, viz.  
1. MDM2 drives and links postischemic inflammation and epithelial healing, two major 
danger response programs upon acute tissue injuries.  
2. MDM2 blockade protected the kidney from AKI despite enhanced p53 activation 
documenting that intrarenal inflammation, not oxidative stress per se, accounts for 
most of the tubular damage in postischemic AKI.  
3. MDM2 forces the podocytes to undergo NF-κB-mediated cell death, for example, 
mitotic catastrophe, a form of cell death resulting from abnormal mitotic spindles and 
chromosome segregation with multiple nuclei in postmitotic cells
85,87
.  
4. MDM2 blockade rather increased the podocyte number in AN despite p53 activation 
questioning the well-established concept of p53 dependent apoptosis as a common 
cause of podocyte loss in AN.  
5. Podocyte MDM2 might have a similar role like podocyte mTOR in podocyte injury.  
6. Therapeutic MDM2 blockade, e.g., in cancer, may hold the risk of impaired 
(epithelial) healing during AKI. On the other hand, MDM2 antagonists may delay or 
halt the progression of glomerular disorders to CKD. 
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The novel finding coming out of this study is that MDM2 blockade inhibits the induction of 
pro-inflammatory mediators that mediate leukocyte recruitment and tissue damage in the 
postischemic kidney. This sterile inflammatory response is triggered by danger-associated 
molecules that are released from dying cells and that activate TLR2 and TLR4 in renal 
parenchymal cells and in intrarenal dendritic cells
5,20,25,26,28,149
. The common signaling adaptor 
MyD88 links TLR activation to NF-κB translocation to the nucleus where it binds to the 
promoter of multiple pro-inflammatory target genes such as ILs, TNF, and chemokines
155
. 
Blocking NF-κB signaling consistently abrogates postischemic inflammation and AKI156-158, 
and lack of NF-κB signaling inhibitors aggravates renal ischemia–reperfusion injury159. The 
data showed here now document that MDM2 is required for TLR-induced NF-κB signaling. 
MDM2 was previously shown to induce the expression of the p65 subunit of NF-κB by 
binding to the Sp1 site at the p65 promoter in acute lymphoblastic leukemia cells
160
, but in the 
present study the MDM2-dependent regulation of p65, IκB, or MAP kinases was not 
observed. Rather a nonredundant role of MDM2 for NF-κB interaction with its binding site at 
a target gene promoter was observed. This observations are also consistent with a previous 
report showing that MDM2 blockade with nutlin-3a suppresses LPS-induced lung 
inflammation and that nutlin-3a impairs NF-κB DNA binding in neutrophils without affecting 
other components of the TLR signaling pathway
161
. It is important to note that this pro-
inflammatory role of MDM2 is p53 independent as clearly documented by the studies with 
p53- and p53/Mdm2-deficient cells and the studies in wild-type and p53-deficient mice. 
In the postischemic kidney, this p53-independent pro-inflammatory effect of MDM2 operates 
simultaneously to its suppression of p53. This was documented by western blotting of kidney 
proteins from nutlin-3a-treated mice, which displayed a consistent increase of the protein 
levels of total p53 and its phosphorylated form. These data document the dual modulatory 
effect of MDM2 on p53, i.e., its E3 ligase activity that degrades p53 and its direct inhibitory 
effect on p53 activation
162
. Increased p53 activity mediates postischemic tubular cell death 
and renal dysfunction, and blocking p53 activation attenuates AKI
9,10
. These data suggest that 
MDM2 blockade should aggravate postischemic AKI. But the observations in the present 
study were exactly the opposite, suggesting that in the early phase of AKI the p53-
independent pro-inflammatory effect of MDM2 overrides its p53-dependent effects. This 
finding also clearly documents that postischemic AKI largely results from secondary 
inflammatory tissue damage as an unnecessary and inappropriate danger response to oxidative 
stress. 
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Figure 35 Dual effects of murine double minute-2 blockade during acute kidney injury A. In its best-
described role, murine double minute-2 (MDM2) interacts with p53 via an N-terminal domain and targets p53 
for nuclear export or, by E3 ubiquitin ligase activity, for proteosomal degradation. During AKI, this function of 
MDM2 may limit p53-mediated upregulation of proapoptotic genes and, by so doing, promote tubular epithelial 
cell survival and proliferation during the regenerative phase. B. In the presence of the MDM2 blocker nutlin-3a 
(n3a), p53-mediated transcription of proapoptotic gene products such as BAD, BID, and NOXA is enhanced, 
favoring increased epithelial cell apoptosis and inferior recovery of kidney function. C. In cells of the innate 
immune system such as intrarenal dendritic cells, MDM2 may facilitate binding of the transcription nuclear 
factor-κB (NF-κB) to promoter regions of genes encoding pro-inflammatory mediators such as tumor necrosis 
factor (TNF), CXCL2, and CCL2 in response to Toll-like receptor (TLR) signaling initiated by release of 
danger-associated molecular patterns (DAMPs). This property of mdm2 promotes a potent inflammatory 
response that may exacerbate early tissue damage and cell loss during AKI. D. For this mechanism of action of 
MDM2, the inhibitor nutlin-3a is associated with attenuated NF-κB-driven transcription of pro-inflammatory 
genes, resulting in a restrained inflammatory response and reduced early tissue injury and loss of kidney 
function. (adapted from McNocholas BA et. al. 
163
). 
 
This p53-independent pro-inflammatory effect of MDM2 was also observed in AN. MDM2 
blockade with nutlin-3a suppressed the renal cytokines and leukocyte infiltrates in the early  
(mostly glomerular injury) phase and the later (glomerular and tubulointerstitial injury) phase 
and therefore protected the mice from AN. This indicates that nutlin-3a as such suppresses 
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AN like other NF-κB antagonists100. From these and other studies it can be assumed that 
suppressing intraglomerular or tubulointerstitial cytokine and chemokine expression avoids 
the activation of endothelial cells which is a requirement for the adhesion and transmigration 
of leukocytes in both of these compartments of the kidney
151
. Leukocytes arriving into the 
pro-inflammatory environment of glomerular or tubular injury get activated and amplify the 
inflammatory milieu they found upon arrival which may indirectly contribute to podocyte loss 
and subsequent FSGS
40
. 
During the later phase of AKI, there is a shift of the balance between inflammation and 
regeneration (epithelial healing) towards regeneration
164
. In accordance with this, in the 
present study we observed that once the acute inflammatory response had resolved, MDM2-
mediated inhibition of p53's effects on the induction of proapoptotic genes and tubular cell 
death was dominant and was required for tubular regeneration. Epithelial healing is an 
important element of tissue regeneration after injury of outer or inner surfaces
150
. The 
regeneration of injured tubular cells is conceptually identical to (scratch-induced) injury of 
cell monolayers in culture and involves the proliferation and migration of surviving epithelial 
cells
44
. MDM2 blockade impaired this process 5 days after renal ischemia–reperfusion by 
tilting cell cycle regulation toward p53-dependent tubular cell apoptosis as evidenced by a 
lack of this phenomenon in p53-deficient mice. The capacity of the MDM2 antagonist nutlin-
3a to impair epithelial healing may be clinically important when nutlins will be used to treat 
cancer
142,165,166
, and it should be considered that the desired antiproliferative and proapoptotic 
effects of nutlins in cancer might affect tissue regeneration upon (renal) injuries or wound 
healing after surgery
167,168
.  
Inside the glomerulus, podocytes are terminally differentiated visceral epithelial cells. MDM2 
staining of the kidney sections revealed that, being an epithelial cell lineage MDM2 is 
strongly expressed by podocytes. Moreover, the finding that MDM2 mediates NF-ĸB-
dependent death of tubular epithelial cells during postischemic renal inflammation and rather 
inhibits p53-dependent tubular cell apoptosis raised the question whether MDM2 also 
modulates podocyte survival upon injury and how. MDM2 inhibition reactivates p53-
mediated tumor cell senescence and apoptosis
28,119,142
 making it a rational for use as an 
anticancer strategy. Therefore, the speculation was that MDM2 blockade would massively 
enhance podocyte apoptosis during glomerular injury. On the contrary, it has been found that 
it rather protects podocytes from an inflammatory form of cell death, known as mitotic 
catastrophe
86,87,112,169
. These data question podocyte apoptosis as a dominant form of  
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Figure 36 Effect of MDM2 blockade during adriamycin nephropathy A. MDM2 interacts with p53 and 
facilitates its nuclear export as well as proteosomal degradation by ubiquitylation. During AN, this function of 
MDM2 lowers the p21 levels, a G1 restriction point, and therefore forces the podocyte to undergo cell division 
(mitosis). As podocyte are highly differentiated cells, they cannot divide and thus die by a process called mitotic 
catastrophe. B. In the presence of MDM2 antagonist, nutlin-3a, the p53 dependent expression of p21 is 
increased. This increase in p21 (G1 restriction point) forbid the podocyte from undergoing cell division 
(mitosis), resulting in podocyte survival. 
 
cell death during podocyte loss, at least in AN, and document that MDM2 has a non-
redundant role in driving renal inflammation, podocyte loss, FSGS, and its progression to 
CKD. Current concepts of podocyte loss mostly name apoptosis, even though apoptotic 
podocytes are rarely captured in-vivo, e.g. by TUNEL staining
82
.  The TUNEL+ podocytes 
were undetectable in AN in the present study, even upon MDM2 blockade which was 
expected to increase p53-dependent apoptosis. Thus, the p53-mediated apoptosis as a major 
element of podocyte loss in AN had been excluded. In contrast, MDM2 blockade rather 
increased podocyte numbers, which implies that MDM2 is a mediator of podocyte loss. The 
in-vitro studies revealed that MDM2 blockade directly protected podocytes from adriamycin-
induced death. A careful analysis identified that MDM2 blockade protected podocytes from 
mitotic catastrophe. Physiologically, mitotic catastrophe prevents an oncogenic growth of 
aneuploid cells with significant DNA damage
85
. In the present study adriamycin, an alkylating 
agent that inhibits topoisomerase II, kills podocytes in-vitro and in-vivo by inducing oxygen 
radical formation and DNA damage which then fuel to cause mitotic catastrophe
86,112,170
. 
These data are in line with previous studies that had demonstrated that podocytes may enter 
the S-phase of the cell cycle to increase DNA synthesis and to undergo hypertrophy which 
they can survive until they get pushed to pass the p21-governed G1 restriction point and 
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complete the cell cycle
83,86,88,170-173
. Notch activation, complement activity, and obviously also 
MDM2 signaling, suppress p21 so that podocyte loss can involve mitotic catastrophe 
whenever cell cycle arrest genes like p21 are suppressed or absent
84,86,88,174
. 
But why can podocytes not simply complete the cell cycle? Forming the mitotic spindle 
involves the entire actin cytoskeleton which is hardly compatible with maintaining the 
secondary foot-processes and, therefore, the slit membranes. Mature podocytes also lack 
proteins like aurora B which are necessary to complete cytokinesis, i.e. the division of the 
cytoplams
86
. Therefore, multinucleated podocytes can be observed in podocytopathies but are 
most common in collapsing FSGS
173,175
. These multinucleated podocytes indicate aneuploid, 
i.e. severely damaged, podocytes which are destined to die, rather than to regenerate the 
injured podocyte monolayer
61,173
. 
The dual role of MDM2 on inflammation and cell cycle control is conceptually similar to the 
respective functional roles of the mTOR pathway
176
. As such it is noteworthy that MDM2 
blockade with nutlin-3a elicits identical effects on AN in Balb/c mice as well as renal IRI in 
both Balb/c and C57BL/6 mice as mTOR inhibition with rapamycin
177-179
. It is likely that 
podocyte MDM2 has a similar role like podocyte mTOR which was recently shown to be an 
important element of podocyte injury in diabetic glomerulosclerosis
180,181
. 
In summary, a rapid inflammatory response and subsequent epithelial healing represent 
effective response programs to minimize the risk of fatal infections after dermal injuries. In 
the kidney, however, postischemic inflammation is of no benefit in this regard but determines 
largely postischemic AKI. Also, the inflammatory environment generated after the podocyte 
injury in the kidney further contributes to the podocyte loss and glomerulosclerosis.  The data 
presented here shows that MDM2 is constitutively and predominantly expressed in all 
epithelial segments of the nephron from podocytes and PECs to tubular epithelial cells all 
along the nephron. MDM2 is not regulated during acute and chronic kidney injury but still 
significantly contributes to renal immunopathology. MDM2 actively contributes to the early 
inflammatory response after renal IRI, promoting the inflammation in tubular compartment as 
well as during AN, promoting podocyte loss e.g. via mitotic catastrophe and the subsequent 
inflammatory response in the glomerular and tubulointerstitial compartment. 
The data identifies MDM2 as a factor that drives early postischemic renal inflammation and 
subsequent epithelial healing via two independent functional properties, i.e., facilitating NF-
κB-target gene expression and suppressing p53-mediated cell cycle arrest and apoptosis 
respectively. Therefore, the data confirms MDM2 as a link between inflammation and 
Discussion  82 
 
epithelial healing during acute kidney injury. Moreover, the data presented here indicates that, 
p53-dependent podocyte apoptosis does not contribute to podocyte loss in AN, which 
questions p53-dependent apoptosis as a common cause of podocyte loss in-vivo. 
However, there are some limitations to the conclusions drawn from the present study. Viz. 1. 
The study lacks supporting evidence from human experiments. But these have to await the 
results of the ongoing clinical trials with nutlin-3a in cancer. 2. Similar experiments in cell 
type-specific Mdm2-deficient mice will be useful to understand the role of MDM-2 in a 
particular cell type during kidney injury. These are currently performed in the laboratory by 
another staff member. 3. Only a single dose of nutlin-3a was used throughout the study based 
on the previous studies in the laboratory. But it might be possible that higher doses are even 
more effective. 4. The conclusions were drawn from studying only one animal model of AKI 
and one of CKD. It might be possible that MDM-2 blockade leads to different results in other 
disease models. 
 
To summarize, therapeutic MDM2 blockade, e.g., in cancer, may hold the risk of impaired 
(epithelial) healing during AKI. On the other hand, MDM2 antagonists may delay or halt the 
progression of glomerular disorders to CKD by reducing renal inflammation and by directly 
protecting podocytes from mitotic catastrophe. 
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 7. Abbrevations 
 
A  R 
AKI Acute Kidney Injury  ROS Reactive Oxygen Species 
AN Adriamycin Nephropathy  T 
B  THP Tamm–Horsfall protein  
BUN Blood Urea Nitrogen  TLR Toll Like Receptor 
C  TUNEL Terminal Deoxytransferase Uridine  
CDK Cyclin Dependent Kinase    Triphosphate Nick End Labeling  
CKD Chronic Kidney Disease    
D    
DAMP Danger Asscociated Molecular Pattern    
DCs Dendritic Cells    
E    
ESRD End Stage Renal Diasease    
F    
FSGS Focal Segmental Glomerulosclerosis    
G    
GBM Glomerular Basement Membrane    
GFP Green Flouroscent Protein    
GFR Glomerular Filtration Rate    
I    
ICAM-1 Intracellular Adhesion Molecule-1    
IRI Ischemic Reperfusion Injury    
K    
KIM-1 Kidney Injury Molecule-1    
L    
LPS Lipopolysaccharide    
LRC Label Retaining Cells    
M    
MDM2 Murine Double Minute-2    
MEFs Mouse Embryonic Fibroblasts    
N    
NGAL 
Neutrophil gelatinase-associated 
lipocalin     
NK Natural Killer    
P    
PAMP Pattern Asscociated Molecular Pattern    
PECs Parietal Epithelial Cells    
PPR Pattern Recognition Receptors    
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8. Appendix 
Composition of buffers used 
FACS buffer :  
Sterile DPBS    500 ml  
Na Azide    500 mg (0.1 % )  
BSA     1 g (0.2 %)  
 
Paris Buffer:  
20 mM Tris-HCL, 125 mM NaCl, 10 mM KCl, 10 mM Sodium acetate, 
5 mM Glucose.  
For 1000 ml:  
Tris-HCL (MW 121.14)  2.4228 g  
NaCl (MW 58.44)   7.31 g  
KCl (MW 74.56)   0.74556 g  
Sod. Acetate (MW 82.03) 0.8203 g  
D-Glucose (MW 180.16)  0.9 g  
 
10X HBSS (Hank’s Balanced Saline Solution) with Ca, Mg:  
For 1000 ml  
KCl     4 g  
KH
2
PO
4    
0.6 g  
NaCl     80 g  
Na
2
HPO
4
.2H
2
O   0.621 g  
NaHCO
3    
3.5 g  
CaCl
2     
1.4 g (or CaCl
2
.2H
2
O 1.854 g)  
MgCl
2
.6H
2
O   1 g  
MgSO
4
.7H
2
O    1 g  
D-Glucose    10 g  
Dissolve in 900 ml of distilled water and adjust to pH 7.4 with 1N HCl or 1N NaOH. 
Make up the volume with distilled water to 1000 ml.  
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10X HBSS (Hank’s Balanced Saline Solution) without Ca, Mg:  
For 1000 ml  
KCl     4 g  
KH2PO4    0.6 g 
NaCl     80 g  
Na
2
HPO
4
.2H
2
O   0.621 g  
Dissolve in 1000 ml and autoclave.  
 
DNAse stock solution (1 mg/ml):  
DNAse (type III) 15000 U/6 mg (Sigma D5025)  
To prepared 1 mg/ml solution: 
Add 6 ml of 50 % (w/v) Glycerol in 20 mM Tris-HCl (pH 7.5), 1 mM MgCl2. 
Can be kept at – 20 
0
C for several weeks.  
Caution: Solution is stable only for 1 week at 4
0
C.  
 
50 % Glycerol in 20 mM Tris-HCl (pH 7.5), 1 mM MgCl
2
:  
a. 0.48 g of Tris-HCl in 100 ml of distilled water, adjust pH to 7.4 (= 40 mM)  
b. 50 ml of Glycerol 100 % + 50 ml of 40 mM Tris-HCl (20 mM)  
c. Add 100 ul of 1M MgCl
2 
solution.  
 
Collagenase / DNAse solution:  
1 mg/ml Collagenase, 0.1 mg/ml DNAse in 1X HBSS (with Ca, Mg)  
For 10 ml:  
Collagenase (type I) (Sigma C0130)  10 mg  
1 mg/ml DNAse stock solution   1 ml  
HBSS (with Ca, Mg)    9 ml  
To be preheated in 37 
0
C water bath before use.  
Caution: Prepare freshly every time (Stable only for few days)  
 
Collagenase solution:  
1 mg/ml Collagenase in 1X HBSS (with Ca, Mg)  
For 10 ml:  
Collagenase (type I)    10 mg  
HBSS (with Ca, Mg)    10 ml  
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To be preheated in 37 
0
C water bath before use.  
Caution: Prepare freshly every time (Stable only for few days)  
 
EDTA 2 mM: 
EDTA 7.44 mg in 10 ml HBSS (without Ca, Mg) 
To be preheated in 37 0C water bath before use. 
 
MACS Buffer: 
PBS pH 7.2 
0.5% bovine serum albumin 
2 mM EDTA 
 
Citrate buffer 10X: 
110 mM Sodiumcitrate in ddH2O 
with 2N NaOH to pH 6 
 
PBS: 
2.74 M NaCl 
54 mM KCl 
30 mM KH2PO4 
130 mM Na2HPO4 
in ddH2O 
Adjust pH to 7.5 with HCl 
 
Gel Running Buffer (10x): 
  Tris        30g 
  Glycine    144g 
  SDS          5g 
 Make up volume to 1000ml (pH 8.3) 
 
Transfer Buffer (1x): 
  Tris         1.5g 
  Glycine  7.2g 
 Make up volume to 500ml  
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TBS (10x): 
  Tris        24.23g 
  NaCl       80.06g 
  Conc. HCL around 17.5ml 
 Make up volume to 1000ml (pH 7.6) 
 
TBS-T (1x): 
  TBS (1x)      1000ml 
  Tween 20     1ml 
 
Sample buffer: 
  Milipore water   3,8 ml 
0,5 M Tris HCl, pH 6,8  1 ml 
Glycerol   0,8 ml 
10% SDS   1,6 ml 
2- mercaptoehanol  0,4 ml 
1% (w/v) bromophenol blue  0,4 ml 
  Total  8 ml 
 
Separating Buffer (1x): 
  Tris (1.5mM)         18,2g 
  SDS             400mg 
 Make up volume to 100ml (pH 8.8) 
 
Stacking Buffer (1x): 
  Tris (0.5mM)       6,05g 
  SDS             400mg 
 Make up volume to 100ml (pH 6.8) 
 
Staining solution: 
  Methanol   500ml 
  Acetic acid    100ml 
  Water    400ml 
 Coomasie Brilliant blue R : 2.5 g  (0.25%) 
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Destaining solution: 
  Methanol   150ml 
  Acetic acid    100ml 
  Water    750ml 
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